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resumo 
 
 
Os vírus são agentes infeciosos oportunistas. Os diferentes passos de um ciclo 
de vida viral, incluindo a entrada do vírus na célula, a replicação do seu 
genoma e a formação de novas partículas virais requerem interações com os 
diferentes componentes celulares do hospedeiro, nomeadamente com 
organelos. Neste projeto, propomos estudar dois tipos diferentes de vírus que 
afetam dois mecanismos distintos de sobrevivência celular: a influência do 
Citomegalovírus de humano (HCMV) na resposta imunitária inata e o efeito do 
Vírus da Influenza A (IAV) na proteostase. 
O HCMV pode estar associado com consequências graves para a saúde da 
população, uma vez que tem a capacidade para estabelecer uma infeção 
latente e persistente no hospedeiro. Este vírus codifica para a vMIA, uma 
proteína anti-apoptótica que se localiza nos peroxissomas e nas mitocôndrias, 
induzindo a sua fragmentação e inibindo a resposta antiviral celular que é 
estabelecida em ambos. Com isto, sugerimos mapear os domínios da vMIA 
responsáveis pelas alterações na morfologia dos organelos e na inibição da 
resposta imune. Os nossos resultados revelaram que a sequência de 
aminoácidos 115-130 poderá ser importante para a fragmentação dos 
organelos. Também descobrimos que a proteína m38.5 do Citomegalovírus de 
ratinho (MCMV), análoga à vMIA, parece localizar nos peroxissomas, induzir a 
sua fragmentação e claramente inibir a resposta antiviral dependente deste 
organelo. Estes resultados sugerem que este vírus poderá ser útil para 
complementar os nossos resultados com experiências animais ou no contexto 
de infeção viral. 
O IAV é o agente causativo da maioria das epidemias anuais em humanos. 
Durante a infeção com IAV, ocorre acumulação de proteínas com conformação 
errada e a formação de locais especializados de replicação viral, resultando na 
formação de agregados insolúveis ou inclusões. Neste estudo, propusemos 
determinar se a infeção com IAV conduz à acumulação de proteína com pré-
disponibilidade para formar agressomas. Os nossos resultados, embora 
preliminares, sugerem que existe formação destas estruturas durante a infeção 
viral, previamente à libertação do genoma viral no citoplasma. 
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abstract 
 
Viruses are small opportunistic infectious agents. Virus entry, replication and 
assembly are dynamic and coordinated processes that require precise 
interactions with host components, often with cellular organelles. Hence, we 
proposed to study two different viruses affecting two distinct cellular 
surveillance mechanisms: Human Cytomegalovirus (HCMV) and Influenza A 
Virus (IAV) influence on the innate immune response and proteostasis, 
respectively. 
 
HCMV might be associated with additional long-term health consequences in 
human due to its ability to establish a lifelong persistent latent infection. HCMV 
encodes vMIA, an anti-apoptotic protein known to co-localize at peroxisomes 
and mitochondria, induce their fragmentation and inhibit the downstream 
cellular antiviral response that is established at both organelles. In the present 
work, we aimed to characterize the role of vMIA in the peroxisomal-MAVS 
dependent antiviral response. We proposed to map the vMIA domains 
responsible for the organelles’ morphology changes and innate immune 
response inhibition. Our results revealed that the 115-130 amino acid sequence 
might be important for the organelles’ fragmentation. We also found that m38.5, 
an analogue of vMIA in murine CMV (MCMV) seems to localize at 
peroxisomes, induce the organelle’s fragmentation and clearly inhibit the 
peroxisome-dependent antiviral immune response. These results suggest that 
this virus may be useful to complement our results with experiments performed 
in animals or in the context of a viral infection. 
 
IAV is the causative agent for most of the annual epidemic in humans. During 
IAV infection, it occurs the accumulation of unfolded proteins and the formation 
of specialized sites of viral replication, resulting in the formation of insoluble 
aggregates or inclusions. In this study, we proposed to determine whether and 
how IAV infection leads to aggresomal-prone proteins accumulation. Our 
preliminary results suggest aggresomes formation during viral infection, 
previous to the vRNP release in to the cytoplasm. 
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Human Cytomegalovirus and Innate Immunity  
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Human Cytomegalovirus and Innate Immunity 
1.1 Human Cytomegalovirus 
According to the International Comittee on Taxanomy of Viruses (ICTV, 2011), cytomegalovirus (CMV) 
belongs to the subfamily Betaherpesvirinae, family Herpesviridae and order Herpesvirales. It takes part 
of the Group I of Baltimore’s Classification of double stranded desoxyribonucleic acid (dsDNA)1. Several 
species of CMV have been identified and classified for different mammals, being humans and monkeys 
its natural hosts.  
Cytomegaloviruses are widely distributed in nature and are characterized generally by slow growth, 
restricted species specificity, and by inducing a typical cytopathic effect on infected cells involving 
specific nuclear and cytoplasmic inclusions as well as cell enlargement. Human herpesvirus 5 (HHV-5), 
commonly named as Human cytomegalovirus (HCMV), is common in the human population and is 
becoming increasingly apparent that it might be associated with additional long-term health 
consequences due to its ability to establish a lifelong persistent latent infection2. Murine CMV (MCMV), 
a natural mouse pathogen, shares a high degree of sequence homology and biology with HCMV, and is a 
widely used model to study HCMV infection3.  
1.2 Epidemiology  
HCMV is a highly widespread pathogen that infects people of all ages, with higher seroprevalence in the 
elderly, being more common in developing countries and in communities with lower socioeconomic 
status4.  
Upon primary infection, the virus is intermittently shed in multiple body fluids, hence, transmission can 
occur via saliva, sexual contact, blood transfusion and solid-organ or hematopoietic stem cell 
transplantation5. Recurrent infection occurs with reactivation of latent virus in response to 
immunosuppression, or reinfection with a different strain in a seropositive individual for CMV. 
Considering an immunocompetent host, primary infection is almost always benign with minimal or no 
clinical manifestation, yet it can result in horizontal or vertical transmission6. Occasionally, healthy 
individuals develop a self-limited mononucleosis syndrome, sore throat, glandular fever and a mild 
hepatitis.  Howecer, HCMV infection turns into a leading cause of illness and life-threatening in 
immunocompromised subsets of the population, including patients who are undergoing hemodialysis 
or receiving immunosuppressive drugs, as well as patients with cancer, HIV-infected, or organ 
transplant recipients7,8. In this setting, CMV serves as a major opportunistic pathogen, being a lifelong 
burden to immune dysfunction. 
Also, HCMV has been described as one of the major causes of congenital disorder, including severe and 
permanent neurological injury in newborns. Vertical transmission can occur transplacentally, during 
childbirth, or through breastfeeding9.   
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1.3 Genome and morphology 
HCMV has a spherical to pleomorphic structure, and is the largest of the eight known human 
herpesviruses, with 150-200 nm in diameter and a 230 kilo base pairs (kbp) non-segmented genome 
encoding for over than 200 conventional open reading frames (ORFs). 
The HCMV virion (Figure 1) consists of a core containing a long non-segmented linear dsDNA 
surrounded by a symmetric icosahedral capsid. These components are enclosed into a lipid bilayer 
envelope derived from the host cell endoplasmic reticulum (ER)-Golgi compartments, that contains at 
least 20 virus-encoded glycoprotein complexes involved in cell attachment and penetration. Between 
the envelope and the capsid is an amorphous, proteinaceous asymmetric matrix designated the 
tegument holding few cellular and viral ribonucleic acid (RNA) and the majority of the virion proteins, 
which can either have a structural role, a modulatory function of the host cell response to infection or 
be important for the virion (dis)assembly10. In addition to viral DNA, HCMV virions also carry mRNAs 
into the host cells11.  
 
Figure 1 Schematic representation of HCMV structure. The dsDNA genome is surrounded by a symmetric 
icosahedral capsid and enclosed into a lipid bilayer spiked with at least 20-virus encoded glycoprotein complexes, 
as gB, gH and gL that mediate virus entry in human cells. In between, there is the tegument, a proteinaceous matrix. 
 
1.4 Life cycle 
Virus Entry: Attachment and fusion of infectious particles with the host cell membrane requires 
interaction of several viral glycoproteins (e.g. gB and gH12) and cell-surface proteoglycans and receptors 
(e.g. epidermal growth factor receptor (EGFR) and β1 integrins). HCMV can enter the cells either through 
endocytosis or direct fusion of the envelope with the cellular membrane (Figure 2, step 1). 
After internalization, nucleocapsids, virion mRNA and tegument proteins are released into the 
cytoplasm (Figure 2, step 2a and 2b), where virion mRNAs are translated. Tegument proteins bound to 
the capsid are believed to interact with the host microtubule machinery to transport viral capsids to into 
nucleus, where the genome is released (Figure 2, step 3) and where viral transcription, genome 
replication and encapsidation occurs13.  
Viral Gene Expression and Replication: HCMV starts to express its genes using the cellular 
transcriptional machinery. Productive replication leads to the temporal-coordinated synthesis of three 
classes of proteins, each regulating different aspects of the infectious cycle. Tegument proteins by 
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incoming virions tightly inhibit the initial steps of immune response and initiate the time-dependent 
cascade of viral genome expression13.  
Immediate early genes (0–4 hours after infection) have been shown to be responsible for the early 
cytopathic effect, to protect the virus against innate host immunity and be involved in the regulation of 
transcription. Early viral genes (4–48 hours after infection) are involved in viral DNA replication and 
further transcriptional regulation. Furthermore, late genes are expressed during the remainder of 
infection up to viral egress and typically code for structural proteins14.  
When latent, viral genomes take the form of closed circular episome in tandem with the host cell DNA 
and retain the capacity to replicate using the host cell replication machinery, although being expressed 
only a small subset of viral genes15.  
Virion assembly and release: Late gene expression drives capsid assembly in nuclear viral factories 
and nuclear egress to the cytoplasm (Figure 2, step 4). Capsids are then associated with tegument 
proteins and trafficked to the viral assembly complex, comprised by host’s endoplasmic reticulum, Golgi 
apparatus and endosomal machinery, to acquire a tegument layer and an envelope13. Furthermore, 
cellular and viral RNAs are packaged into virions in proportion to their intracellular concentration11 
(Figure 2, step 5).  
 
Figure 2 Schematic representation of HCMV life cycle in a human cell. HCMV attaches to the cell via interactions 
between viral glycoproteins (e.g., gB and gH) and specific surface receptors (e.g. EGFR), and is incorporated either 
through direct fusion or the endocytic pathway (1), followed by the release of  nucleocapsids (2a), viral proteins 
and viral mRNA (2b) into the cytoplasm. These mRNA are translated and the nucleocapsids are translocated into 
the nucleus, where viral DNA is released (3), and initiates the expression of IE genes. Viral replication and 
maturation involves the encapsulation of replicated viral DNA as capsids (4), which are then transported to the 
cytoplasm. Secondary envelopment occurs in at the ER-Golgi intermediate compartment (5). This is followed by 
virion release by exocytosis at the plasma membrane (6). Adapted from Crough et al., 200916.  
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Enveloped infectious particles along with non-infectious dense bodies are next released into the 
extracellular space by exocytosis (Figure 2, step 6). HCMV is a lytically replicating virus, thus after it 
causes massive cell enlargement, its life cycle culminates with the destruction of the infected cell. 
Treatment 
The most common treatment for patients with weakened immune system who have HCMV infection 
symptoms is prophylactic antiviral medication. Currently, all licensed anti-HCMV drugs are nucleoside 
analogs and all share the same fundamental mechanism of action, namely the inhibition of viral DNA 
polymerase, and consequently viral replication, being ineffective against a latent virus. In clinical 
practice, these drugs are frequently used for broader indications related to the treatment and prevention 
of HCMV infection in immunocompromised hosts9.  
Cytogam®, Cytomegalovirus Immune Globulin Intravenous is an immunoglobulin G containing a 
consistent number of antibodies to HCMV. Alone or in combination with an antiviral agent, this 
medication has been approved by Food and Drug Administration (FDA) for the prophylaxis of HCMV 
disease in high-risk patients having an organ transplant and reduce the risk of HCMV-related diseases 
and death in some of the highest-risk patients9,17. 
1.5 Antiviral innate immune sensing  
The innate immune system on eukaryotic organisms holds very well-defined defense mechanisms 
against evading pathogens in early phases of infection. The innate antiviral immunity is activated with 
the detection of evolutionarily conserved structures termed pathogen-associated molecular patterns 
(PAMPs), by a set of host’s germline-encoded pattern-recognition receptors (PRRs). Endogenous 
products produced during cell damage or tissue destruction upon infection also stimulate PRRs18,19.  
According on their localization, PRRs may be classified into membrane-bound PRRs, that include Toll-
like receptors (TLRs) and C-type lectin receptors (CLRs); and cytoplasmic PRRs, including nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene-I (RIG-I)-like 
receptors (RLRs), as well as cytosolic viral DNA sensors such as cyclic guanosine monophosphate–
adenosine monophosphate (cGAMP) synthase (cGAS)18. The recognition of viral PAMPs, that mainly 
consists of viral nucleic acids, such as 5’ triphosphate terminal RNA, is possible due to endosomal TLR, 
cytosolic DNA sensors and cytosolic RLRs20.  
Tool-like receptors 
TLRs are considered the primary sensors of pathogens19. TLRs are type I membrane glycoproteins and 
consist of one extracellular and one cytoplasmic domains, required for PAMP recognition and 
downstream signaling, respectively. Following TLR activation by PAMPs, a variety of adaptor molecules 
are activated and induce a signaling cascade that culminates in the activation of transcription factors 
that will regulate the expression of interferon (IFN), cytokines and chemokines20.  
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To date, 10 TLR family members have been identified in humans. TLR1, 2, 4, 5 and 6 are primarily 
expressed on the cell surface, whether TLR3, 7, 8 and 9 are exclusively expressed within endocytic 
compartments20. 
HCMV virions were shown to trigger inflammatory cytokine responses via envelope gB and gH 
recognition by TLR2, in a mechanism dependent of nuclear factor kappa B (NF-κB) activation21, and 
were proven to induce TLR4 signaling components and downstream IFN expression22. On the other 
hand, endosomal TLR3 and 9 were demonstrated as essential components in the innate immune defense 
to MCMV infection23. 
Cyclic GMP-AMP synthase (cGAS) 
cGAS is a cytosolic DNA sensor belonging to the nucleotidyltransferase family. Once bound to DNA, cGAS 
catalyzes cGAMP synthesis, which in turn binds to and activates the ER protein stimulator of interferon 
genes (STING). This protein is a critical signaling molecule of the innate immune response against DNA 
viruses, once it further activates the antiviral type I IFN signaling pathway. 
It is known that UL122, which encodes the immediate-early 2 86 kilo Dalton (kDa) protein (IE86), 
strongly abolished cGAMP-mediated type I interferon (IFN) promoter activation, as it facilitates 
proteasome-dependent degradation of STING24. Also, the HCMV tegument protein UL82 was identified 
as a negative regulator of STING-dependent antiviral responses25. Furthermore, STING was described as 
necessary for the first phase of type I IFN production that limits early CMV replication, proven that the 
cGAS-STING pathway has a pivotal role in the initial detection of CMV infection26.  
RIG-I-like receptors (RLRs) 
RLR family are expressed in most cell and tissue types and consists in three molecules: retinoic acid-
inducible gene (RIG-I), melanoma differentiation-associated gene-5 (MDA5) and laboratory of genetics 
and physiology 2 (LGP2). These sensors recognize the RNA from RNA viruses in the cytoplasm of 
infected cells and induce inflammatory cytokines and type I interferons.  
Structurally, all three members contain an intermediate DExD/H-box RNA helicase domain which is 
involved in recognition and binding to pathogen nucleotides, as well as adenosine triphosphate (ATP) 
hydrolysis-involved conformational changes; and a C-terminal repressor domain (RD)27,28. RIG-I and 
MDA5 also contain two N-terminal tandem caspase activation and recruitment domains (CARDs) that 
are essential for downstream signaling cascade29,30. The RD of RIG-I maintains the receptor in a closed, 
stable and inactive conformation that constrains the activation of the downstream signaling, being 
necessary its activation via conformational changes to expose its RIG-I CARD to further initiate antiviral 
signaling. Opposing to RIG-I, MDA5 has the CARD domains permanently exposed20.  
Although RIG-I and MDA-5 have specificities for different ligands, effective sensing of PAMPs rapidly 
induces host immune responses via the activation of intracellular signaling cascades that ultimately 
leads to the induction of IFN and IFN-stimulated genes (ISGs), as well as pro-inflammatory cytokines19,31, 
8 
 
which subsequently may function as direct antiviral effectors, preventing viral genome replication, viral 
particle assembly, or virion release from infected cells, and shape the adaptive immune response18. 
1.6 RIG-I-MAVS signaling  
Mitochondrial anti-viral signaling (MAVS), also known as IFN-β promoter stimulator (IPS-1), CARD 
adaptor inducing IFN-β (CARDIF), and virus-induced signaling adaptor (VISA), is localized in the outer 
mitochondrial membrane32, peroxisomes33 and mitochondria-associated membranes (MAM)32 . Both 
peroxisomal and mitochondrial MAVS have specific signaling pathways which result in different but 
complementing activities20 and are required for antiviral responses with either temporal or functional 
differences, which suggest that they may be recruiting distinct subsets of adaptor proteins. The different 
kinetics of ISG expression induction by peroxisomal and mitochondrial MAVS suggest that more than 
one mechanism of RLR-induced ISG expression may operate in virus-infected cells29.  
Peroxisomes and mitochondria are ubiquitous organelles present in eukaryotic cells, with remarkably 
dynamic and high plasticity, capable of moving throughout the cell in a motor protein-dependent 
manner along cytoskeletal tracks. They continuously adapt their abundance, morphology, distribution, 
enzyme content and activity, according to the metabolic needs, or physiological changes in their cellular 
environment upon external stimuli. Peroxisomal and mitochondrial abundance varies according to the 
cell type and is regulated by organelle formation, half-life, and autophagy-mediated degradation34,35.  
Mitochondria are double membrane-bound organelles containing their own genomes and 
transcription/translation systems. It can adopt a variety of different shapes that can range from small, 
spherical compartments of 0.1 to 1µm to elongated tubulo-reticular networks up to 10 μm34. 
Peroxisomes are bordered by a single-membrane that surrounds a granular matrix, are devoid of DNA 
or protein synthesis machinery and are spread throughout the cytoplasm of most eukaryotic cells36. 
Similarly, its shape and size vary greatly in different tissues, ranging from a spherical to rod-like form 
and from 0.1 to 0.5 μm in diameter, but they can also appear as elongated tubular organelles and small, 
tubulo-reticular networks with up to 5 μm, which are frequently associated with lipid droplets34,37.  
Besides cooperating in the establishment of an effective cellular antiviral response, peroxisomes and 
mitochondria cooperate coordinately in managing diverse metabolic processes in mammals, as 
maintenance of cellular reactive oxygen species (ROS) homeostasis, fatty acids oxidation,  and serve as 
signaling platforms that modulate diverse physiological and pathological processes including 
inflammation and cell fate transitions34.  
Fluctuations in organelle abundance can be expected to have significant effects on their functional 
output, and to adjust organelle quantity in response to changing environmental and developmental 
stimuli, cells coordinate the formation of new organelles and their subsequent degradation once they 
are excessive or non-functional.  
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Upon infection, the recognition and binding of exogenous 5’-ppp panhandle dsRNA structures to RD 
leads to a conformational switch of RIG-I, which releases the autorepressed CARDs18 (Figure 3, step 1). 
Activated RIG-I recruits its downstream adaptor MAVS (Figure 3, step 2). MAVS N-terminal contains a 
CARD-like domain and a proline-rich region allows MAVS to bind with upstream signaling molecules 
such as RIG-I and MDA5, through homotypic CARD–CARD-mediated interactions. MAVS activation 
induces the formation of a detergent-resistant prion fibre-like active aggregates that may involve the 
CARD domains of several MAVS38.   
 
 
Figure 3 Organelle-Specific MAVS Signaling. Upon infection, detection of exogenous dsRNA structures by RIG-I 
(1) releases the autorepressed CARDs, leading to its activation (2). Activated RIG-I recruits and bind to 
mitochondrial and peroxisomal MAVS, through homotypic CARD–CARD-mediated interactions (3). Peroxisomal 
MAVS was shown is essential for the rapid expression of antiviral genes (ISGs) that will block early antiviral effects, 
via IRF1 and IRF3 (5). On the other hand, mitochondrial MAVS seems to act with slower kinetics, inducing delayed 
but sustained responses (6); it promotes type I IFN-dependent ISG expressions, via IRF2, 3 and 6 (7). Once secreted, 
IFNs bind to specific cell surface type I IFN receptors, leading to the activation of the JAK–STAT pathway, thus 
generating an amplifying loop leading to RIG-I accumulation during infection and additional ISGs transcription, 
involved in the generation of the antiviral state (8). Adapted from Sharma et al, 201039. 
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Peroxisomal MAVS was shown to be involved in early rapid, however transient responses, mitochondrial 
MAVS seems to act with slower kinetics, inducing delayed but long-lasting responses20,33. Perhaps the 
peroxisomal pathway establishes a first outburst of antiviral effector proteins to temporarily block viral 
replication, while the mitochondrial pathway can induce a stronger and sustained antiviral state 
although delayed, to clear out the infection33.   
Moreover, peroxisomal MAVS leads to the induction of ISGs via the transcription factors interferon 
regulatory factor 1 (IRF1) and IRF3, independent of type I IFN production33, whereas mitochondrial 
MAVS promote type I IFN-dependent ISG expressions, via IRF2, 3 and 620,29(Figure 3). The main 
advantage of peroxisomal early response is the absence of pro-inflammatory cytokines secretion that 
would most definitely cause unnecessary cell damage. However, if this fails to control viral infection, the 
mitochondrial pathway comes into action, stimulating a more powerful and persistent immune 
response, in an attempt to prevent further viral spread39.  
Once secreted, IFNs bind to specific cell surface type I IFN receptors, leading to the expression of the 
interferon-stimulated gene factor 3 (ISGF3) through the activation of the Janus kinase-signal 
transducers and activators of transcritpion (JAK–STAT) pathway. ISGF3 then translocates to the nucleus 
and coordinates the transcription of hundreds of ISGs including RIG-I, thus generating an amplifying 
loop leading to RIG-I accumulation during infection and additional ISGs transcription, involved in the 
generation of the antiviral state18,29 (Figure 3, step 8).  
1.7 Virus-induced apoptosis 
Viruses are capable of exploit and reprogram the host metabolism to replicate, what may lead to the 
host’s cell death20. Apoptosis, both extrinsic and intrinsic pathways, schematized in Figure 6, can occur 
in response to cellular stress induced by viral infection3.  
The extrinsic pathway is a major mechanism of host immune clearance of virally infected cells. Death 
receptors, as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor (TRAILR) 
and FAS receptor (FasR), can activate initiator caspases, namely caspase-8 and -10, through 
dimerization mediated by adaptor proteins, such as FAS-associated Death Domain Protein (FADD), 
TNFR-associated Death Domain Protein (TRADD) and Receptor Interacting Protein Kinase-1 (RIPK1). 
The intrinsic pathway of apoptosis requires mitochondrial outer membrane permeabilization (MOMP), 
with subsequent release of mitochondrial interspaced proteins, as cytochrome c, that promotes the 
activation of apoptotic caspases. Bcl-2 family proteins function by regulating the integrity of the 
mitochondrial outer membrane, and comprise three functional subgroups: BH3-only proteins that act 
as stress sensors and initiate apoptosis; the effector proteins Bax and Bak that mediate MOMP; and pro-
survival Bcl-2 proteins that maintain mitochondrial membrane integrity. Bcl-2 proteins have the 
capacity to bind to Bax and Bak and thus prevent their activation. BH3-only proteins initiate apoptosis 
by binding to Bcl-2 proteins and thereby releasing Bax and Bak, or by interaction with Bax and Bak and 
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directly catalyze their activation. In healthy cells, Bax and Bak exist as inert monomers, but as apoptosis 
proceeds the proteins undergo conformational changes resulting in the formation of large homo-
oligomers that permeabilize the mitochondrial membrane3,40. 
The extrinsic cell death pathway can intersect with the intrinsic signaling through the caspase-8-
mediated cleavage of BH3 interacting-domain death agonist (Bid) to truncated Bid (t-Bid), which 
translocates to the mitochondria and interacts with Bax and Bak, to induce MOMP.  
 
1.8 vMIA’s dependent CMV evasion from antiviral cellular responses 
Goldmacher et al41 demonstrated that CMV infection provides resistance to apoptosis through the viral 
mitochondria-localized inhibitor of apoptosis (vMIA) protein. This protein is the product of UL37 exon 
1 (pUL37x1) and, besides being an important regulator of viral response to stress42, it has been 
additionally shown to induce the release of ER calcium stores43. vMIA has two domains that are 
necessary and sufficient for its anti-apoptotic function (Figure 4) encoded by Tyr5-Leu34 and Asp118 
and Arg147 segments41,44. Furthermore, the mitochondrial localization signaling is located within the 
amino acid 2-30 sequence44,45, and one or several amino acids within the 135-141 segment of vMIA are 
essential for its interaction with Bax and further apoptosis inhibition46,47.  
 
Figure 4 Representation of vMIA anti-apoptotic domains. Adapted from Hayajneh, 200144. 
 
Organelle’s morphology and RIG-I-MAVS signaling 
Upon HCMV infection, vMIA was shown to promote viral replication by efficiently increasing 
mitochondrial biogenesis in fibroblasts48. vMIA is also localized at peroxisomes, interacts with MAVS 
and specifically diminishes the peroxisomal MAVS-dependent production of ISGs31.  
Mitochondria are continuously remodeled through cycles of fusion and fission34, whereas peroxisomes 
have distinct biogenesis pathways. Unlike mitochondria, mature peroxisomes cannot fuse with one 
another, thus new peroxisomes must arise from division of pre-existing peroxisomes49 or de novo 
formation50. A well-defined sequence of morphological changes, including elongation, constriction, and 
fission, is most likely the major proliferation process35.  
Both organelles share key components of their fission/division machinery mammals51, including a 
dynamin-like protein/dynamin-related-protein GTPase (DLP/DRP1), and its membrane adaptors 
mitochondrial fission protein 1 (FIS1), mitochondrial fission factor (MFF), and ganglioside-induced 
differentiation-associated protein (GDAP1). Overexpression or downregulation of their function has 
been shown to induce its fragmentation or elongation, respectively35. 
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DLP/DRP1 is a predominantly cytosolic protein known to function in elongation and fission, not 
required for organelle constriction. Recruitment of DLP/DRP1 to peroxisomal or mitochondrial division 
sites depends on FIS1, MFF, and GDAP1 recruitment to organelle membranes. Additionally, peroxisome 
membrane elongation requires members of the Pex11p family of peroxisomal membrane proteins 
(PMP) that initiates membrane remodeling and the formation of a tubular membrane extension on one 
side of the peroxisome34,52. This process is schematically represented in Figure 5. 
 
 
Figure 5 Representation of mitochondrial (A) and peroxisomal (B) growth and division in mammalian cells. 
A well-defined sequence of morphological changes, including growth/elongation, constriction and fission 
contributes to organelles proliferation. In Mefs of wild-type cells, mitochondria are characterized by a network of 
extended tubules (up to 10 μm) distributed roughly throughout the cytoplasm (A1). Replicative mitochondrial 
fission is initiated by recruitment of cytosolic DLP/DRP1 to the constriction sites, by the adaptor proteins MFF and 
FIS1, located in the outer mitochondrial membrane (A2). Fragmented mitochondrial appeared mostly as sphere or 
oval shaped (A3). On the other hand, the activation of Pex11 at pre-existing peroxisomes initiates membrane 
remodeling and the formation of a tubular membrane extension on one side of the peroxisome (B1). Subsequently, 
the extension grows and acquires specific set of proteins, as Pex11p and Fis1 (B2). Pex11p and Mff-DLP1 complex 
concentrate at the sites of constriction (B3). In Mefs, peroxisomes appear as elongated tubular organelles and small 
tubule-reticular networks (up to 5 μm) and, when fragmented, for instance as a consequence of DLP/DRP1 
silencing31 (B4), they appear significantly smaller and in higher number. 
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The peroxisomal de novo formation might involve the budding and fusion of pre-peroxisomal vesicles 
derived from the ER or the mitochondrial membrane. It can be explained by a semi-autonomous model 
of peroxisome formation, whereby the ER and mitochondria supply existing peroxisomes with essential 
membrane lipids and proteins, including Pex19, Pex3 or Pex16, to allow its growth and division34,50.  
In addition, vMIA had already been shown to induce mitochondrial fragmentation as a necessary step 
for the inhibition of the mitochondrial-dependent signaling pathway53,54. It also induces peroxisomal 
fragmentation, a mechanism is not essential for vMIA to specifically inhibit signaling downstream the 
peroxisomal MAVS. Thus, vMIA appears to act at both organelles via distinct mechanisms31.  
Apoptosis 
With a slow replication cycle, HCMV depends on the sustained cell viability and, to prevent the 
premature death of infected cells, the virus is known to block apoptotic signaling pathways and subvert 
the host antiviral response31.  
Several viral immediate early gene products with antiapoptotic properties have been identified in 
HCMV, including, UL36, UL37 and UL38, represented in figure 6. The UL36-38 immediate-early locus is 
highly conserved among HCMV strains and it is required for its replication, once it encodes for proteins 
that inhibit the ability of an infected cell to activate cell-degrading caspases44.  
The UL36 gene product is known as vICA (or pUL36), which stands for viral inhibitor of caspase-8 
activation. vICA blocks the extrinsic cell death pathway by binding to procaspase-8 and blocking its 
cleavage and subsequently activation3.  
Furthermore, HCMV deficient for UL37x1 gene, that encodes for vMIA, has a severe growth defect as a 
result of strong induction of apoptosis in infected cells55,56.  
vMIA is known to inhibit apoptosis through inactivation of Bax. It binds and sequesters Bax at 
mitochondria’s outer membrane in form of high-molecular weight and inactive oligomers that lacks 
capacity to induce MOMP46. Whether vMIA is capable of inhibiting apoptosis though Bak is still 
controversial46,57,58.  
Overall, vMIA prevents the formation of the mitochondrial permeability transition pore and inhibit the 
release of cytochrome c and pro-apoptotic factors into the cytoplasm, thereby preventing the activation 
of downstream executioner caspases31. The functional properties of vMIA’s localization resemble those 
of Bcl-2 family anti-apoptotic proteins. However, vMIA does not possess homology to any BH domains 
and its function is independent of t-BID low concentrations55. 
Lastly, UL38 has recently been shown to encode a cytosolic protein pUL38 that suppresses the ER-stress 
response, by inducing the expression of chaperones through activating transcription factor 4 (ATF4) 
and suppression of pro-apoptotic c-Jun N-terminal kinase (JNK) activity3.  
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MCMV encodes distinct inhibitors of Bax and Bak, m38.5 and m41.1, respectively. m38.5 protein is 
encoded at analogous position as HCMV vMIA within the respective viral genomes. Although they share 
little sequence homology, both seem to localize to mitochondria and inhibit Bax in an analogous manner, 
therefore preventing apoptosis. m38.5 was proposed to be a functional ortholog of vMIA in MCMV59,60. 
A second MCMV-derived inhibitor, m41.1, associates with Bak at the mitochondrial membrane and acts 
as a viral inhibitor of Bak oligomerization (vIBO) from HCMV. Optimal replication of MCMV depends 
upon m38.5 and m41.1, whose combined activities maintain mitochondrial integrity88. 
 
 
Figure 6 Inhibition of apoptosis by CMV. vMIA and vIBO inhibit MOMP and release of pro-apoptotic factors, as 
cytochrome c by interacting with BAX and BAK, respectively. MCMV encodes two specific inhibitors, m38.5 and 
m41.1, HCMV has only pUL37x1, whether the pUL37x1 protein is BAX-specific or inhibits both BAK and BAX is still 
controversial. The extrinsic apoptosis pathway initiated by death receptors is blocked by vICA, which is encoded by 
HCMV UL36 and MCMV M36 gene, respectively. APAF1: apoptotic protease activating factor 1; FasL: Fas ligand; 
FADD: Fas-associated death domain protein; RIPK1: receptor interacting protein kinase-1; TNFα: tumor necrosis 
factor α; TNFR: TNF receptor; TRADD: TNFR-associated death domain protein; t-BID: truncated BH3-interacting 
domain death agonist. Adapted from Brune et al., 20173. 
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Influenza A Virus and Proteostasis 
2.1 Influenza A virus 
Influenza viruses are among the most common viruses causing high morbidity and mortality. Influenza 
A virus (IAV) has been the causative agent for most of the annual epidemic in humans and the major 
pandemics of influenza in the last century61,62.   
According to ICTV (2011), IAV belongs to the Influenzavirus A genus of the Orthomyxoviridae family that 
comprises enveloped viruses with segmented, negative-sense single-stranded RNA (ssRNA) genome62, 
capable of bind sialic acid in mucoproteins. IAV is designed as a type V virus concerning the Baltimore’s 
classification system1. Up to this date, 16 different HA (H1 to H16) and 9 NA (N1 to N9) subtypes have 
been identified62, being H1, H2 and H3 the virus subtypes identified in humans.  
Epidemiology  
Influenza viruses continuously undergo antigenic evolution, either by antigenic drift or antigenic shift. 
Antigenic drift involves the accumulation of point mutations within the viral RNA genome, particularly 
in genes that code for antigenic sites. These mutations and the emerging virus strain variants gain 
selective advantages and evade preexisting immunity, being generally responsible for winter epidemic 
outbreaks. On the other hand, antigenic shift implies genetic re assortment of RNA segments from 
different virus strain or different viruses. The new virus subtype arises presenting a novel phenotype 
with pandemic potential, since there is no immunity to the new virus subtype in the population, allowing 
the virus to spread rapidly and cause high morbidity and mortality61.  
Both seasonal and pandemic influenza can afflict people of all ages, and most cases will result in self-
limited illness in which the person recovers fully without treatment. Seasonal influenza is an acute 
respiratory disease that is characterized by the sudden onset of high fever, cough, headache and 
inflammation of the upper respiratory tree and trachea. In the elderly, in infants, and in people with 
chronic diseases, typical seasonal influenza is associated with especially high risk of developing severe 
complications within hours, as hemorrhagic bronchitis, pneumonia, and ultimately death in as little as 
48 hours after the onset of symptoms61. Pandemic outbreaks cause most of its severe or fatal disease in 
younger people, either in chronic patients and healthy individuals, and caused many more cases of viral 
pneumonia than is normally seen with seasonal influenza.   
2.2 Genome and morphology 
The genome of IAV consists of eight single-stranded, negative-sense linear RNA segments (-) ssRNA, 
encoding for 12 to 14 proteins depending on the strain most of which are necessary for efficient virus 
replication in host cells and for virion formation. Genome total size is about 3,5kb and the segments size 
range from 890 to 2341 nucleotides.  
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The three largest RNA segments encode the three viral RNA-dependent RNA polymerase (RdRP) 
proteins: polymerase acidic protein (PA), polymerase basic protein 1 (PB1) and PB2. The three 
intermediate-size RNA segments encode HA, NA and nucleoprotein (NP). The larger of the remaining 
two segments encodes M1 and M2 matrix proteins, and the smaller one encodes two nonstructural 
proteins, NS1A and NS261,63. To express spliced forms of viral proteins, as M2 and NS2, the virus uses the 
host cell’s splicing machinery, while prevents the host cell from using it to process host cell messenger 
RNA (mRNAs), through NS1 interaction with small nuclear RNAs64. 
Each of the eight RNA segments is separately enclosed in the virion in the form of ribonucleoprotein 
complexes (vRNPs), wrapped in a helical conformation with NP (one subunit binds ~20 nucleotides of 
vRNA and the vRdRp in both 3’ and 5’ ends62. 
The influenza virions are known to display many forms, sometimes taking an irregular shape. They are 
generally spherical or elliptical in shape, ranging from approximately 80 to 120 nm in diameter, and 
occasional elongated or filamentous, reaching more than 20 µm in length. Regardless of their shape, all 
virions incorporate an organized set of eight RNPs62 (Figure 7). 
The IAV genome is covered by an envelope coat made up of a lipid bilayer, derived from the host cellular 
membrane acquired during the budding, that is known to contain both cholesterol-enriched lipid rafts 
and non-raft lipids. The outer layer of the lipid envelope is spiked with numerous membrane-spanning 
viral glycoproteins, HA, NA and M2. The type I transmembrane HA is the most abundant envelope 
protein (~80%), followed by NA (~17%). M2, a highly selective type III transmembrane ion channel, is 
a very minor component, with only 16 to 20 molecules per virion64. The peripheral membrane protein, 
M1, which is one of the most abundant viral proteins in the virion, binds to the lipid envelope to maintain 
virion morphology62. 
 
Figure 7 Schematic representation of IAV virion. Eigh (-) ssRNA segments are inclosed into an lipid bilayer 
envelope spicked with viral glycoproteins. 
 
2.3 Replication cycle 
Attachment: The replication cycle begins when the viral surface HA binds to the sialic acid residues 
from glycoproteins or glycolipids on the host cells membrane64,65 (Figure 8, step 1). The specificity of HA 
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binding between species depends on the nature of the glycosidic linkage between the terminal sialic acid 
and the penultimate galactose residue on the receptor. Human influenza viruses preferentially bind to 
sialic acids attached to galactose in an α (2,6) configuration64.  
Entry into host cell: After successful binding, virion internalization occurs essentially by receptor-
mediated endocytosis and the virus is transported into the cell in an endocytic vesicle (Figure 8, step 2). 
The low pH in the endosome triggers conformational changes in the HA protein, which leads the fusion 
between the viral envelope and the endosomal membrane63,64, with the formation of a fusion pore 
through which the viral genetic material is released. It also stimulates the proton flow into the virus via 
M2, which then weakens the interaction between the M1 and the vRNPs, promoting their dissociation.  
Nuclear transport: After being released into the cytoplasm, the vRNP are transported to the nucleus 
(Figure 8, step 3) by cellular nuclear import machinery recognition of the nuclear localization sequences 
(NLS) present in ribonucleoproteins63, where it undergoes transcription and replication processes.  
Transcription and Replication: The (-) vRNA strand is used for the synthesis of capped, 
polyadenylated mRNAs, a readable form that it is further converted into proteins through process 
termed cap-snatching; and full-length positive sense (+) complementary RNA (cRNA), that will serve as 
template to produce more (-) vRNA strands to be then packed into the new virions. Both processes are 
carried out by the viral RdRp enzyme and, due to its short proteasome, the virus hijacks the host 
transcription machinery for its own purposes.  
During the cap-snatching process, short oligomers from host pre-mRNA are recognized and bound by 
the viral PB2 subunit66, cleaved at the 5’ end by the PA endonuclease domain67 and then used to prime 
mRNA synthesis via PB1 subunit68,69. The viral genome is thereby transcribed using host capped mRNA 
segments as primers for initiation of viral mRNA synthesis, which ultimately leads to the synthesis of 
capped translatable viral mRNAs63. On the other hand, viral genome replication involves unprimed 
synthesis of an exact full-length copy of the (-) vRNA into (+) cRNA, which lacks both the 5’ capped 
primer and 3’ polyadenylation tail and can be used as templates for further (-) vRNA synthesis further 
used in the assembly of vRNA complexes69,70.  
NP molecules are required for both steps of replication and are deposited on the cRNA and vRNA during 
RNA synthesis. Both NP and the RNA polymerase components are complexed with newly synthesized 
vRNA to form vRNPs69.  
Nucleus export of vRNPs and Translation: vRNPs are exported to the cytoplasm, either for translation 
into viral proteins and further assembly of new virus particles.  
Synthesis and folding of viral core proteins occur entirely in the cytosol, taking advantage of host cell 
factors to perform viral mRNA translation70. The synthesis of viral envelope proteins HA, M2 and NA 
also starts in the cytosol but are further folded and processed in the host ER and the Golgi apparatus 
where they undergo post-translational modifications, as glycosylation63. Subsequently, the proteins are 
20 
 
additionally modified and transported through the trans-Golgi network to the plasma membrane of the 
cell (Figure 8, step 4).  
M1 interact with HA and NA, forming patches with a high density of HA and NA. Subsequently, newly 
formed RNPs interact actively with the M1 lining at these patches, which prevents re-entry of RNPs into 
the nucleus and direct them towards the assembly site on the apical membrane of polarized epithelial 
cells. This ensures that progeny viruses are releases back to the airways. The viral proteins accumulate 
in the cholesterol rich membrane region named lipid rafts, believed to be the site of virion formation. 
Virion assembly: The packaging of vRNPs favors the formation of infectious virus particles with all eight 
RNA segments required for efficient infection70 (Figure 8, step 5). After the budding of all viral proteins 
and vRNP complexes, viral NA cleaves the sialic acid residues on cellular surface glycoproteins or 
glycolipids, which is bind to HA during the process. Doing that, recently formed virions are released from 
the host cell's surface (Figure 8, step 6) and start to spread and infection further cells throughout the 
respiratory tract64.  
 
Figure 8 IAV life cycle. The cycle begins when the viral surface HA binds to the sialic acid residues on host cells 
membrane (1). IAVs is predominantly internalized by endocytosis and the virus is transported into the cell in an 
endosome (2). The low pH inside the endosome induces the formation of a fusion pore through which the viral 
genetic material is released and imported to the nucleus (3), where it undergoes transcription and replication 
processes. Viral core proteins synthesis occurs entirely in the cytosol, whether viral envelope proteins synthesis 
suffer further processing in the ER and Golgi apparatus (4), and both accumulate at the host membrane. After the 
budding of all viral proteins and vRNP complexes (5), recently formed virions are released from the host cell's 
surface and start to spread and infection further cells (6). Adapted from Das et al., 201063. 
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As an acute lytic viral infection, the entire process seriously disrupts the normal physiology of the 
infected cell and causes the destruction of its membrane, and consequently cell death and desquamation 
of the respiratory epithelium. However, cell lysis does not occur until the cell has produced many 
thousands of new virus particles during the latent phase of infection. 
2.4 Treatment 
Effective measures against influenza A diseases include prevention of infection by either administration 
of antiviral drugs or vaccination. Antiviral drugs can have both therapeutic and prophylactic effects, but 
to prevent disease they must be administered continuously at times of high influenza activity61. 
Oseltamivir (Tamiflu®) is a selective NA inhibitor that induces the aggregation of viral particles on the 
host cell surface, preventing  the release and spreading of the new progeny viruses71. Amantadine, a M2 
ion channel blocker, slows the dissociation of M1 from the RNPs and the viral membrane, inhibiting 
subsequent steps in the viral life cycle72.  
Nevertheless, vaccination is still the primary strategy for prevention and control of influenza virus, and 
both inactivated and attenuated vaccines are effective. Once virus subtypes are distinguishable 
serologically, and the continuous viral antigenic drift of IAV makes once effective vaccines ineffective 
after a few years' time, having the requirement for regular updates of the composition of the influenza 
vaccine and annual revaccination is thus recommended for those at high risk61.  
2.5 Proteostasis and Quality Control Machinery 
To be functional, most proteins go through a succession of folding intermediate states and adopt a 
defined three-dimensional native structure. A protein is correctly folded if it has attained its native 
conformation after required co- or post-translational modifications.  
During the folding process, partially folded proteins, as folding intermediates and misfolded conformers, 
expose some hydrophobic domains that are typically hidden in the native structure, which can lead to 
nonproductive associations and are prone to trigger protein aggregation73. Besides, the proteins in the 
native configuration can undergo unfolding, specially under stress conditions74. 
Misfolded proteins can interfere with normal cellular functions and be potentially toxic. Thus, cellular 
proteostasis maintenance is imperative to ensure successful development, healthy aging, resistance to 
environmental stresses and to minimize homeostasis perturbation by pathogens such as viruses. To 
suppress the formation of protein aggregates, cells have evolved an elaborated quality-control 
machinery (Figure 9) that can adapt to the severity of protein damage and acts through ensuring the 
fidelity of transcription and translation, and induction of stress responses75–78.  
Distinct surveillance mechanisms that respond to misfolded and unfolded proteins have been 
characterized in the cytoplasm, in the ER and in the mitochondria. For instance, various molecular 
chaperones and/or chaperonins have evolved to assist post-translationally folding of newly synthesized 
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proteins and refolding of proteins damaged by stress and cellular injuries. For what is known, they occur 
ubiquitously in all cellular compartments that sustain protein synthesis and folding reactions. Also, 
while small monomeric proteins can fold in their absence in vivo, medium- to large-sized multidomain 
proteins critically require chaperones to undergo a correct fold79.  
Most cellular proteins are folded directly after translation in the cytosol with the assistance of 
chaperones, foldases and lectines80 These molecules, mainly the heat shock proteins (HSPs) HSP60 and 
HSP7078, bind to and stabilize exposed hydrophobic residues, prevent incorrect intra– and 
intermolecular interactions between partially folded or unfolded polypeptides, prevent aggregation and 
promote the refolding of denatured model substrates and the proper formation of noncovalent 
interactions that lead to the desired folded state81.  
 
Figure 9 A schematic representation of the cellular quality control machinery involved in the maintenance 
of proteostasis. Molecular chaperones support the folding of nascent polypeptides and refolding of proteins 
damaged by stress and cellular injuries. Additionally, they prevent misfolded or unfolded protein from aggregating 
and escort terminally misfolded protein for UPS degradation. The autophagy-lysosomal pathway aids to remove 
protein aggregates formed by the misfolded proteins that have escaped from the surveillance of chaperones and the 
UPS. Adapted from Huabo et al, 200982. 
 
Cellular proteins that are unable to fold properly, among non-functional protein fragments and no longer 
useful proteins, are targeted for degradation by a proteolytic mechanism, termed the ubiquitin–
proteasome system (UPS). This system is found in cytosol and nucleus, and mediates degradation of 
cytosolic, nuclear, secretory and transmembrane proteins. Misfolded secretory and transmembrane 
proteins are first retained in the lumen or the membrane of the ER, retro translocated back to the cytosol 
and delivered to the proteasome83,84. The UPS involves at first the tagging of misfolded proteins with a 
polyubiquitin chain, follow by recognition of the polyubiquitylated tag and degradation by the 
proteasome.  
Furthermore, the autophagy-lysosomal pathway helps to remove protein aggregates formed by the 
aggregation-prone proteins that have escaped from the surveillance of chaperones and the UPS, and 
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defective organelles. First, they are sequestered within an isolated double membrane vesicle, named 
phagophore, to form autophagosomes, which later fuse with lysosomes to form autophagolysosomes, 
where the segregated content is degraded by lysosomal hydrolases85.  
2.6  Protein aggregation and aggresome formation 
When the amount of misfolded proteins in a cell is so high that exceeds the refolding or degradative 
capacity of the quality-control machinery, or when the components of the protein homeostasis 
machinery are disrupted, it leads to the formation and accumulation of insoluble protein aggregates, as 
a consequence of interaction between aggregation-prone conformers78,86. 
In cells, protein misfolding can be promoted due to specific mutations, RNA modification, translational 
errors leading to the misincorporation of amino acids, assembly defects of protein complexes or errors 
during protein folding. Protein aggregates can be either structured, as amyloid, or amorphous. In either 
case, they tend to be insoluble in aqueous or detergent solvents and metabolically stable under 
physiological conditions87.   
In a remarkable variety of degenerative diseases, specific proteins have been found to misfold, aggregate 
and form pathogenic assemblies, ranging from small oligomers to large masses of amyloid. The outcome 
in all cases is the functional compromise of the nervous system, once the aggregated proteins gain a toxic 
function and/or lose their normal function88. However, progressive formation of protein aggregates is 
not necessarily pathogenic, as proved by G. Diane Shelton89, whose results suggested that, although 
increasing in size with age, aggregates formation was not related with other pathological changes nor 
functional deficits.  
During infection, the formation of specialized sites of viral replication can involve extensive 
rearrangement of cellular cytoskeleton and membrane compartments, resulting in the formation of 
insoluble aggregates or inclusions. These aggregates may be part of the innate cellular response that 
recognizes and sequesters viral components90, or possibly will be used by viruses as scaffolds for 
anchoring either viral and host proteins required for replication and assembly, and as a protection from 
host defense91.  
It is conjectured that upon infection, early-induced aggregates, commonly designated as virus factories, 
viroplasm or viral inclusions, indicate sites within perinuclear areas that comprises viral genome and 
proteins involved in virus replication and assembly; and later during infection, these inclusion bodies 
are thought to either form virus factories and/or arise from the accumulation of viral proteins that do 
not become incorporated in the virus at other sites in the cell91.  
The term ‘inclusion bodies’ has been applied to refer to the intracellular foci into which aggregated 
proteins are sequestered. The formation of cytoplasmic inclusion bodies in mammalian cells requires 
active, dynein-based retrograde transport of misfolded protein on microtubules92. Microtubule-
dependent cytoplasmic inclusion bodies are generally termed aggresomes.   
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Aggresomes are not permanently present in the cell. The initial aggregation process is likely to occur co-
translationally. If nascent peptides cannot fold correctly, they will co-aggregate to form a single 
aggresomal particle throughout the cytoplasm. Very quickly after their formation, aggresomal particles 
are transported towards the microtubule organizing center (MTOC), where they are sequestered into 
the aggresome92.  
Aggresome formation is initiated by the formation of smaller aggregates in the periphery, which then 
move in a dynein-based manner along the microtubule cytoskeleton to the final perinuclear site at the 
MTOC, implying that it is an aggregate of aggregates86. Their overall structure and size depends both on 
the aggregating substrate and the host cell. However, most aggresomes appear as a single sphere of 1-
3μm diameter or as an extended ribbon, enriched in components of molecular chaperones and 
proteasome components86, and are surrounded by a cage-like vimentin structure contribute to their 
stability92. 
Transportation machinery involves a microtubule-associated deacetylase, histone deacetylase 6 
(HDAC6), a cytoplasmic enzyme that promotes autophagic clearance of protein aggregates and protect 
cells from cytotoxic accumulation of misfolded proteins (Figure 10). It functions as an adaptor that binds 
polyubiquitin chains of substrates and the microtubule motor protein dynein, thereby mediating the 
transport of polyubiquitylated cargo along microtubules towards the MTOC during aggresome 
formation93.  
 
 
Figure 10 IAV hijacks aggresome processing machinery during virus entry. IAV hijacks endocytosis, travels to 
late endosomes in the vicinity of the MTOC (1). In LEs the low pH (5.5–5.0) triggers HA acidification and fusion of 
the viral envelope with endosomal membrane (2). The fusion pore exposes the viral core containing unanchored 
ubiquitin (Ub) chains to the cytosol (3), inducing a mechanism similar to aggresome processing. Adapted from 
Rudnicka et al., 201694. 
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IAV requires HDAC6 ubiquitin-binding function, taking advantage of the aggresome processing 
machinery for host cell entry and especially for capsid uncoating94,95. The fusion pore formed between 
the viral envelope and the endosomal membrane during the IAV life cycle exposes the viral core that 
contains unanchored ubiquitin chains to the cytosol, which recruit HDAC6 and activate the aggresome 
processing machinery. HDAC6 binds to matrix protein M1, dynein, and myosin, and promotes capsid 
disassembly and uncoating: M1 becomes dispersed in the cytosol and the vRNPs are released and further 
imported to the nucleus94. Therefore, unanchored ubiquitin carried by IAV might activate HDAC6 similar 
to aggresome processing. This mechanism is briefly represented in Figure 10. 
 
2.7 Unfolded protein response 
The unfolded protein response (UPR) is a wide range of integrated signaling pathways that act as a stress 
response mechanisms to cope with conditions of stress at the cellular or organelle-specific level80,96.  
The UPR in the ER  (Figure 11) is induced when homeostasis is disrupted by imbalances of protein 
folding demand and ER-dependent folding capacity97. ER proteostasis perturbations, as a consequence 
of protein overexpression, viral infections, glucose starvation, disturbance of intracellular calcium, 
oxygen deprivation, toxic exposure and changes in redox state98–101,  may lead to accumulation of 
unfolded proteins and its aggregation within the ER, which induces ER stress.  
In eukaryotic cells, the ER is a dynamic tubular network involved in protein homeostasis, metabolic ATP-
demanding processes, such as gluconeogenesis and biosynthesis of phospholipids, and calcium 
buffering102,103. In the ER lumen, proteins are processed and modified into their native conformation, in 
order to be directed and delivered to their proper target sites within the secretory pathway, displayed 
on the cell surface or released extracellularly96,104. As an organelle for folding and modifications of 
proteins, the ER is loaded with extremely high concentration of proteins (>100 mg/ml), at which co-
aggregation between proteins and/or polypeptides is clearly promoted. Therefore, the lumen of the ER 
needs a unique cellular environment that promotes processing and prevents aggregation105.  
In the ER, UPR is mediated by three main sensors that reside in the ER membrane: inositol-requiring 
enzyme 1 (IRE1), double-strand RNA-activated protein kinase RNA (PKR)-like ER kinase (PERK) and 
activating transcription factor 6 (ATF6), each of which have luminal domains that detect misfolded 
proteins in the ER and cytoplasmic effector domains that transduce signaling to the transcriptional or 
transductional apparatus100.  
UPR induces temporally coordinated mechanisms, allied to the expansion of the ER membrane network 
and simultaneous induction of the expanded organelle space filling with newly synthesized protein-
folding and quality control complexes103,104. In resting cells, these three sensors are maintained in 
inactive states through interaction with the binding immunoglobulin protein (BiP) via their luminal 
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domain102. During stress, BiP dissociates from these sensors as it is recruited by unfolded proteins to 
assist their folding. The cytosolic sides from the sensors are auto-activated by trans-phosphorylation102.  
IRE1 is a multi-domain type I transmembrane glycoprotein that has both kinase and RNase 
activities99,100. solely activated by ER stress105. When the cytosolic RNase domain is triggered, it can 
produce either adaptive or death signals103, via regulated IRE1-dependent mRNA decay (RIDD) and 
unconventional splicing of the transcription factor X box-binding protein 1 (XBP1) mRNA99.  
RIDD is constitutionally active once it is necessary for ER homeostasis maintenance, and upon stress 
rises proportionally with its intensity and duration. On the other hand, XBP1 mRNA splicing is activated 
transiently upon ER stress during the adaptive/pro-survival phase, if RIDD is insufficient to maintain ER 
homeostasis. The active spliced XBP1 (sXBP1) mRNA controls the expression of genes related to UPR, as 
chaperones and ER quality control machinery, and modulates phospholipid synthesis, which is required 
for ER membrane expansion during ER stress100,103.  
If these measures succeed, ER homeostasis is restored and IRE1 oligomers disassemble concomitantly 
with IRE1 dephosphorylation. Yet, after prolonged and unmitigated exposure to stress, XBP1 mRNA 
splicing decreases whereas RIDD continues to increase and ultimately induces apoptosis99. Overall, in 
mammals, XBP1 splicing is overactive in cancer with a pro survival output, while RIDD is associated with 
a pro-apoptotic output in diabetes99.  
PERK is a type I transmembrane membrane which the main function is to modulate translation106, 
trough eukaryotic translation initiator factor 2α (eIF2α) phosphorylation. 
 
Figure 11 Schematic representation of UPR pathway. ER stress/induced protein imbalance activates the three 
UPR sensors that culminate into translation attenuation, chaperone induction and aggregation-prone proteins 
degradation. 
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eIF2α is the regulatory subunit of eIF2 that under normal conditions is required in the initiation of mRNA 
translation102. Upon phosphorylation, eIF2α subunit indirectly inhibits the guanine nucleotide exchange 
factor, which normally is necessary to form the tertiary complex with guanosine-5'-triphosphate (GTP) 
and transfer RNA methionine initiator (tRNAiMet) that initiates translation98. That way, it reduces the 
formation of translation initiation complexes, mRNA translation is inhibited and protein synthesis is 
attenuated, reducing the flux of protein into the ER104,106. 
However, there are some mRNAs capable of avoiding the eIF2α translational blockage102,103. One of these 
encodes the activating transcription factor (ATF4) that drives the expression of both cyclic adenosine 
monophosphate (cAMP) response element-binding transcription factor (C/EBP) with pro-survival 
functions and C/EBP homologous protein (CHOP), a pro-apoptotic factor104.  
Lastly, ATF6 is an activating transcription factor synthetized as an ER-resident type II transmembrane 
protein with an ER stress-sensing luminal domain and a cytosolic N-terminal DNA binding domain102. In 
cells undergoing ER stress, ATF6 is packaged into ER transport vesicles and delivered into Golgi 
apparatus104, where it is sequentially cleaved into an active cytosolic fragment (ATF6f) that corresponds 
to its DNA binding domain98,103. ATF6f is then translocated to the nucleus to activate the transcription of 
UPR genes, namely chaperones, being the main outcome is the improvement of the ER folding capacity 
upon stress, providing a positive feedback for the UPR. 
The ER-associated degradation (ERAD) is a pathway along which misfolded and unfolded proteins are 
transported from the ER to the cytosol for proteasomal degradation103, where they are targeted and 
degraded by the UPS 80 or via autophagy102.  
Influenza A virus infection and UPRER inducing 
Viruses can exploit the ER to complete some processes of their life cycle97,107. IAV use UPR to enhance 
viral pathogenesis through facilitating folding and trafficking, affecting receptor interaction108 and 
modulating host immune responses109. Samarasinghe et al. findings’ revealed that acute lung injury 
results from innate sensing of viruses by ER stress, that was found to be responsible for the pathogenicity 
of pandemic IAV110.  
During productive viral infection, as in the case of IAV, large amounts of viral proteins are synthesized 
and modified in infected cells, leading to rapid accumulation of viral proteins and disruption of the ER 
homeostasis. However, if in one way the host mobilizes the UPR in an attempt to restrict virus infection, 
in another some of UPR major consequences are beneficial to viral replication. Thus, UPR could be a 
merely a host response or a result of viral manipulation. Both ways, the outcome could be pathogenic31,33.  
According to Goodman et al. results, P58IPK can interact with and inhibit both PKR and PERK, being a 
critical regulator of both cellular and viral mRNA translation. Yet, they have found that IAV mRNA 
translation and replication is promoted by P58IPK through PKR inhibition, independently of PERK112.  
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Another research conducted by Hassan et al. reported that infection with wild type IAV induces ER stress 
response in human tracheal and bronchial epithelial cells (HTBECs) through the IRE1 branch, with little 
or no concomitant activation of the PERK pathway. They also showed that the virus modulates the stress 
response in the setting of a pre-existing stress by decreasing the activation of the ATF6 pathway. IAV 
also cause a significant induction of several genes, including CHOP, suggesting ER stress response 
activation and apoptosis induction113.  
A different approach was reported by Roberson et al. in murine tracheal epithelial cells (MTECs). Their 
results showed that IAV infection induces ER-stress via ATF6 activation, but not CHOP. They also 
described that IAV mediated-apoptosis in these cells is caspase-12 dependent, which is another hallmark 
of ER-stress in infected cells114.  
Recently, chemical genomics identified the PERK pathway as a cellular target for influenza virus 
inhibition. By screening collections of drugs approved for human use, Landeras-Bueno et al. identified 
Montelukast (MK) as an inhibitor of virus gene expression and validated these results in virus-infected 
cells115. The authors found that IAV leads to attenuation of the PERK-mediated UPR, but does not 
downregulates neither ATF6 or IRE1 arms, in contrast to Hassan and Roberson’s studies113,114. The main 
difference between approaches was that the latter investigators analyzed UPR activation at very late 
times after infection (12 to 48h), long after the virus infection cycle is finished (around 8h). In this 
case115, the authors show clear down-regulation of PERK phosphorylation as early as 6h after virus 
infection. This observation is consistent with the activation of P58IPK. According to their results, MK 
induces PERK phosphorylation and counteracts the influenza virus-induced block of the PERK pathway. 
Therefore, the PERK-mediated UPR was finally considered a potential cellular target for anti-influenza 
virus treatment, and being a cellular target, it may eventually be useful for inhibiting other fast-
replicating RNA viruses. 
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Human Cytomegalovirus and Innate Immunity 
 
HCMV is widely common in the human population and might be associated with additional long-term 
health consequences due to its ability to establish a lifelong persistent latent infection. Upon infection, 
viral components are recognized by intracellular receptors that activate mitochondrial and peroxisomal 
MAVS-mediated antiviral immune response. This virus encodes an anti-apoptotic protein named vMIA 
that localizes at mitochondria and peroxisomes, induces their fragmentation and, more importantly, 
inhibits the cellular antiviral response.  
The main goal of this project was to further characterize the role of vMIA in the peroxisome-MAVS 
dependent antiviral response. To that end, we proposed to study some vMIA sequence-deletion mutants 
in order to map the protein’s domains responsible for peroxisome fragmentation and/or the inhibition 
of the peroxisome-dependent antiviral response. In order to determine the importance of the 
peroxisome-dependent antiviral pathway on the control of the HCMV infection, we aimed to use the 
CRISPR-Cas9 system to create a Pex19 KO cell line where vMia is not able to reach this organelle. We 
furthermore proposed to analyse the role of the MCMV analogue of vMIA, m38.5, on peroxisomes and 
the antiviral cellular response, in order to establish whether we could use this virus to complement our 
studies and be able to perform our analysis in a (cellular or animal) infection context.  
 
Influenza A Virus and Quality Control Machinery 
 
IAV been the causative agent for most of the annual epidemic in humans and the major pandemics of 
influenza in the last century.  Previous studies have shown that, during infection, it occurs the 
accumulation of unfolded proteins within the ER and the formation of specialized sites of viral 
replication, resulting in the formation of insoluble aggregates or inclusions. It is known that IAV 
modulates UPR ER stress-induced and uses the aggresome processing machinery for host cell entry, 
specifically during uncoating.   
In this study we proposed to determine whether IAV infection leads to aggresomal-prone proteins 
accumulation, throughout the immunostaining detection of aggresomes or protein aggregates; 
characterization of the insoluble protein fraction within the cells over time; and the analysis of the 
activation of the UPR pathway. 
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4.1 Materials 
4.1.1 Cell lines 
HeLa Human cervix adenocarcinoma cells; stable cell line expressing the 
fluorescent reporter HSP27-GFP  
Mef MAVS-PEX Mouse Embryonic Fibroblasts with MAVS only at peroxisomes 
A549  Human alveolar basal epithelial adenocarcinoma cells 
HFF Human foreskin fibroblasts 
293T Human embryonic kidney cells 
 
4.1.2 Cell Culture Solutions 
Dulbecco’s Modified Eagle Medium (DMEM) High Glucose w/ L-Glutamine w/o Sodium Pyruvate, Gibco  
Fetal Bovine Serum (FBS), qualified, E.U.-approved, South America origin, Gibco 
Penicillin/Streptomycin, Gibco 
Dulbecco's Phosphate Buffered Saline w/o Calcium w/o Magnesium, Gibco  
Trypsin-EDTA 1X in PBS w/o Calcium w/o Magnesium w/o Phenol Red, Gibco  
Opti-MEM Reduced-Serum Medium (1x), Gibco   
 
4.1.3 Bacterial strains 
Escherichia coli 
 
DH5α 
 
4.1.4 Bacterial Media 
LB/Agar:  
 
 
2g Agar, Formedium 
20 g Lysogeny broth (LB), Fisher Scientific 
1 L ddH2O 
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Antibiotics Ampicillin (Amp), Sigma-Aldrich 
Kanamycin (Kan), Sigma-Aldrich 
4.1.5 Viruses 
Influenza A virus 
 PR8 
 ΔNS1 
 
Influenza virus strain A/Puerto Rico/8/1934 (H1N1) 
Influenza PR8 virus that lacks NS1 protein 
 
4.1.6 Plasmids  
Gene Tag Antibiotic Resistance 
RIG-I-CARD 
vMiaΔ131-147 
vMiaΔ115-130 
vMiaΔ23-34 
vMiaΔ2-23 
m38.5 
 
GFP 
Myc 
Myc 
Myc 
Myc 
HA 
 
Kan 
Amp 
Amp 
Amp 
Amp 
 
 
4.1.7 Vectors 
Transfer pSicoR-CRISPR-Cas9 guideRNA lentiviral vector (RP-418) 
Packaging vector pCMV R8.81 
Envelope vector pMD2.G 
 
4.1.8 Primers and Oligonucleotides 
PCR primers 
 IRF1 
 
 GAPDH 
 
 
 
Manufacture: Eurofins. 
IRF 1 mouse  forward 5’ GGTCAGGACTTGGATATGGAA 3’ 
  reverse 5’ AGTGGTGCTATCTGGTATAATGT 3’ 
 
GAPDH mouse  forward 5’ AGTATGTCGTGGAGTCTA 3’ 
  reverse  5’ CAATCTTGAGTGAGTTGTC 3’ 
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Oligonucleotides for 
CRISPR/Cas9 system 
 PEX19 
 
 
 
Oligo I   forward 5’ AACGCAAGTCGGAGGTAGCAAGA 3’ 
  reverse 5’ AAACTCTTGCTACCTCCGACTTG 3’ 
Oligo II  forward 5’ AACGCTGAGGAAGGCTGTAGTGT 3’ 
  reverse 5’ AAACACACTACAGCCTTCCTCAG 3’ 
 
Oligo III  forward 5’ AACGTGTCGGGGCCGAAGCGGAC 3’ 
  reverse 5’ AAACGTCCGCTTCGGCCCCGACA 3’ 
 
4.1.9 Transfection Reagents 
Lipofectamine® 3000 Transfection Reagent, Invitrogen 
Polyethylenimine (PEI) 
 
4.1.10 Markers and Loading Dyes 
GRS Protein Marker Multicolour Tris-Glicine 4~20%, Grisp   
6x Laemmli Buffer with DTT and Bromophenol Blue 
O' Gene Ruler DNA Ladder Mix, Thermo Fisher 
6x Orange DNA Loading Dye, Thermo Fisher  
 
4.1.11 Enzymes 
Restriction endonucleases 
BsmBI (Esp3I) 
Restriction site 
5’CGTCTC(N)1|3’ 
3’GCAGAG(N)5|5 
Buffer 
10x Fast Digest Buffer, Thermo 
Fisher Scientifics 
 
T4 DNA ligase 
M-MuLV reverse transcriptase 
 
10x T4 DNA ligase Reaction Buffer, New England’s Biolab 
10x M-MuLV Reverse Transcriptase Buffer, New England’s BioLab 
 
4.1.12 Kits 
NucleoBond® Xtra Midi, Macherey-Nagel   
Pierce™ Bovine Serum Albumin (BCA) Protein Assay Kit, Thermo Scientific 
38 
 
Proteostat Aggresome Detection Kit, Enzo  
Protran BA85 Nitrocellulose Blotting Membrane, GE Healthcare   
 
4.1.13 Antibodies 
 
Primary 
 
Species 
 
Production 
Dilution  
Company IMF WB 
PMP70 Mouse Monoclonal 1:200 - Sigma-Aldrich 
HA Rat Monoclonal 1:1000 -  
Myc Rabbit Monoclonal 1:100 - Cell Signaling 
PEX19 Mouse Monoclonal - 1:50 Sigma-Aldrich 
Anti-ATF6 (α) Mouse Monoclonal - 1:400 Stressgen 
Tubulin Mouse Monoclonal - 1:4000 Sigma-Aldrich 
Actin Mouse Monoclonal -   
      
Secondary Species Production 
Dilution 
Company 
IMF WB 
Alexa 488 Rabbit 
Polyclonal  
IgG (H+L) 
1:500 - 
Invitrogen-Molecular 
Probles 
 Mouse 1:400 - 
Alexa 647 Mouse 1:500 - 
TRITC Rabbit 1:200 - 
Jackson Imunoresearch  Mouse 1:100 - 
HoechstDye - - 1:200 - 
IRDye®680CW Mouse Polyclonal 
IgG (H+L) 
- 1:10000 LI-COR 
IRDye®800CW Rabbit - 1:1000 LI-COR 
      
4.1.14 Solutions and Buffers 
Blotting Buffer: 0,05 M Tris, 0,4 M Glycine, 0,05% SDS, 20% Methanol  
BSA 1%:  2% BSA diluted in 1x PBS  
ELB  0.5% Triton X-100, 50mM Hepes pH7, 250mM NaCl, 1mM DTT, 1mM Naf, 
2mM EDTA, 1µM EGTA, 1mM Na3VO4 in ddH2O  
Add protease inhibitors before use: 0,01 mM Foy, 0,25 (v/v) Trasylol, 0,1 mM 
PMSF 
Loading buffer: 
 
1 M Tris pH 6.80, 10% Glycerol, 1 M DTT, 20% SDS, β-Mercaptoethanol, 0,1% 
Bromophenol Blue  
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Milk for Blot blocking:  5 g of powder milk in 100 mL of 1x TBS-T   
Mounting Medium: N-propyl-Gallat: 2.5% (w/v) n-propyl-gallat; 50% glycerol, in PBS  
Mowiol: 12 g Mowiol 4-88, 20 mL Glycerol, 40 mL PBS  
Mounting medium: 3:1 mixture Mowiol with n-propyl-gallate  
1x PBS: 1,37 M NaCl, 80 mM NaHPO4, 0,0268 M KCl, 0,0147 M KH2PO4 pH 7,34, 
prepared from 10x PBS diluted in ddH2O  
PFA 4 %: 20 g PFA in 450 mL ddH2O, 4 drops 1 M NaOH, 50 mL 10x PBS  
Running Buffer 1x:  250 mM Tris, 1,9 M Glycine, 1% SDS  
1x TAE: 
 
0.04 M Tris, 0.02 M Acetic Acid, 1 mM EDTA pH 8, prepared from TAE 50x 
diluted in ddH2O 
TBS-T: 1X TBS-T (100 mM Tris Base, 150 mM sodium chloride and 0,05% Tween-20 
[pH 8])  
0,2%Triton X-100: 0.2% Triton X-100 in 1x PBS    
 
4.1.15 Databases and Software 
Axio Imager Software, Zeiss  
DeNovix DS-11 Software, DeNovix 
Excel, Microsoft  
Graphpad, Prism 7 
Image Lab, Bio-Rad 
Image Studio Software for Odyssey   
National Center for Biotechnology Information (NCBI)  
Quantity One 1-D Analysis Software, Bio-Rad  
Zen Software, Black Edition, Zeiss 
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4.2 Methods 
4.2.1 Cell Culture   
Cell Lines Maintenance 
Mef MAVS-PEX cells and HeLa HSPB1-GFP were kindly provided by Dr. Kagan from Harvard 
Medical School and Dr. Ana Soares from iBiMED, respectively. Both cell strains, along with 293T and HFF 
cells, were routinely cultured and split twice a week in 10øcm culture dishes with DMEM high glucose 
(4,5 g/L) (Gibco ©, Life Technologies, Germany) supplemented with 10% FBS and 1% (100U/mL) of 
penicillin and streptomycin, termed as complete DMEM. The cells were maintained in culture at 37°C in 
a humidified atmosphere containing 5% CO2. 
Confluent cells were washed with PBS and after incubating with 1.5 mL trypsin-EDTA at 37°C 
and 5% CO2. When individual cells separated and detached from the dish surface, cells were 
resuspended in culture medium, centrifuged at 1000 g for 3 minutes at room temperature and either 
divided according to experimental needs and/or seeded in a 1:10 dilution (≈105 cells/mL). 
 
Cell storage, freezing and thawing  
Cells stocks were prepared from confluent cells resuspended in freezing medium (DMEM supplemented 
with 10% FBS and 10% DMSO) and were kept in cryovials aliquots of 1mL. Stocks were frozen in -80°C 
before being placed in the liquid nitrogen tank for cryopreservation.  
When needed, frozen cells were thawed through resuspension with pre-warmed culture medium and 
seeded in a 10øcm culture dishes. After cell adhesion (≈ 5 hours) the medium was replaced by fresh 
growth medium to remove cell debris and DMSO.  
 
4.2.2 Transformation of competent bacteria 
Heat shock transformation  
For bacterial transformation, 1 μL of ligation DNA were added to 45 μL of competent Escherichia coli 
DH5α cells, gently mixed and incubated for 30 minutes on ice. Heat shock was performed by exposing 
bacteria at 42°C for 90 seconds followed by a short incubation on ice, allowing the DNA to be 
incorporated. After, bacteria recuperated in 750 μL of LB for 45 minutes at 37°C 180 g. Bacterial 
suspension was centrifuged for 1 minute at 1700 g and most supernatant was discarded. The pellet was 
resuspended in the remaining supernatant and glass beads helped to spread bacteria in LB/agar plates 
complemented with the appropriate antibiotic, which were incubated at 37°C overnight. The protocol 
was done under a sterile environment and the appropriate controls were used.   
This method was used to obtain midi-preps from vMIA Δ131-147, vMIA Δ23-34 and vMIA Δ2-23. 
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Colonies were picked and inoculated in 3 mL of LB medium with antibiotic for 16 hours at 37°C with 
shaking 180 g. Cell suspension were then grown in 200 mL of LB medium with antibiotic overnight under 
the same conditions. Plasmids were purified following the NucleoBond® Xtra Midi (Macherey-Nagel) 
protocol.  
 
Electroporation 
Prior to electroporation, 50 µl of competent E. coli were mixed with 3 µl of the plasmid to be transformed. 
The mixture is transferred into a chilled plastic or glass 2 mm cuvette which has two aluminum 
electrodes on its sides, ensuring a direct contact between the electrodes and the suspension. 
Electroporation was performed with a 2.5 kV pulse appliance which create an electrostatic field in a cell 
solution. Immediately after, one mL of LB was added to the suspension and it was transferred back into 
the Eppendorf tube, followed by an incubation at 37oC, the bacteria optimal temperature for at least an 
hour to allow recovery of the cells and expression of the plasmid. The suspension was then centrifuged 
at 700 g for 90 seconds, and most supernatant was discarded. The pellet was resuspended in the 
remaining supernatant the bacteria was plated in LB/agar plates complemented with the appropriate 
antibiotic, which were incubated at 37°C overnight. The protocol was done under a sterile environment 
and the appropriate controls were used.   
Several colonies were picked and inoculated in 5 mL of LB medium with antibiotic overnight 37°C with 
shaking 180 g. Plasmid isolation was accomplished through a miniprep protocol. 2 mL of each bacterial 
suspension was centrifuged at 6000 g for 5 minutes. The pellet was resuspended in 300 µl of solution I 
and lysed with 300 µl of solution II, mixed and incubated 5 minutes at room temperature before being 
neutralized with 300 µl of solution III. Then, it was centrifuged at 16 200 g at 4oC and the supernatant 
was kept and mixed with 600 µl of isopropanol. The centrifugation was repeated and the pellet was kept 
and resuspended in 600 µl of 70% ethanol. Once again, the centrifugation was repeated and the pellet 
resuspended in TE buffer with the appropriate volume and store it at 4oC.  
 
Midiprep with the NucleoBond® Xtra Midi 
High-copy plasmids were extracted from 200 ml bacterial cultures, which were inoculated with a single 
bacterial clone in LB medium with the appropriate antibiotic and grown overnight at 37oC and 800 rpm. 
When the optical density reached between 0.2-0.4, bacterial cells were pelleted by centrifugation at 
6000g for 15 minutes at 4oC, and supernatants were discarded. Bacterial cells were completely 
resuspended, lysed, neutralized and centrifuged. Plasmids were then purified following the 
NucleoBond® Xtra Midi (Macherey-Nagel) protocol and the concentration of extracted DNA samples 
was analyzed with Nanodrop (DeNovix). 
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4.2.3 Transient Mammalian Cell Transfection Methods 
Lipofectamine 3000 
Lipofectamine™ 3000 Reagent Protocol (Invitrogen) was followed according to the manufacturer. To 
prepare plasmid DNA-lipid complexes, the transfectable DNA together with P3000 reagent (1:1 ratio) 
was added to Lipofectamine 3000 reagent both diluted in OptiMEM and incubated for 5 minutes at room 
temperature.  The complex formed was then added dropwise to 6-well plates to a final volume of 2 mL 
and it was incubated under growth conditions for 6 hours or 24 hours. This method was used to transfect 
Mefs MAVS-PEX cells with different quantities of DNA (2.7 μg of GFP-RIG-I-CARD, and 3.5 μg vMIA 
mutants/m38.5). 
 
Polyethylenimine (PEI) 
To perform transfection with PEI in 6-well plate, 10 µg plasmid of DNA was diluted in 500 µl of serum-
free DMEM (MOA) and PEI (1 µg/µl) was added to the diluted DNA. The volume of PEI used is based on 
an 8:1 ratio of PEI (µg): total DNA (µg). After mixed, the solution was incubated during 20 minutes at 
room temperature and added to the cells in a dropwise manner. PEI condenses DNA into positively 
charged particles that bind to anionic cell surfaces, the DNA:PEI complex is endocytosed by the cells and 
the DNA released into the cytoplasm. The medium was changed to complete DMEM six hours post-
transfection. 
This procedure was performed to transfect 293T cells with 4 µg of CRISPR-Cas (418), 1 µg of pCMV R8.81 
and 3 µg of pMD2.G vectors, using 32 µl of PEI. All steps were carried out using sterile techniques in a 
laminar flow hood. 
 
4.2.4 Immunocytochemistry 
Immunofluorescence  
Cells grown in 12ømm glass coverslips were washed three times with PBS before being fixated for 20 
minutes with 4% PFA solution, permeabilized with 0,2% Triton X-100 for 10 minutes and blocked with 
1% BSA for 10 minutes, all procedures being performed at room temperatures. After, cells were stained 
with 20 μL of the primary antibody for 1 hour and with the secondary antibody for 1 hour in a humid 
environment, protected from the light. In some cases, the staining with Proteostat Aggresome Dectetion 
kit (Enzo Life Sciences International) was performed, according with the manufacturer’s instructions.  
When needed, cells were incubated with 30 μL of Hoechst dye for 2 minutes. All the incubations were 
done at room temperature and between each step the cells were washed three times with PBS. 
Coverslips were washed in ddH2O, mounted in glass slides with mounting medium (Mowiol) and dried 
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for at least 24 hours. Glass slides were stored at 4°C until observation under a fluorescence or a confocal 
microscope.  
The cells were observed with AxioImager Z1 Zeiss Microscope and AxioVision Software, using 100x/1.40 
oil objective equipped with the appropriate filter combination. Confocal photos were acquired and 
further analyzed with a Zeiss confocal microscope, using 100x/1.40 oil objectives and Zeiss Black Edition 
Software. The lasers used were 488 nm Argon-ion laser, 561 nm DPSS laser and 642 nm HeNe for 
samples stained with Alexa Fluor 488 dye/GFP, TRITC/Proteostat dye and Alexa 647 dyed, respectively.  
 
4.2.5 Reverse transcriptase - quantitative Polymerase Chain Reaction (PCR) 
RNA extraction 
Cells in 6-well plate were washed with PBS and lysed at room temperature with 500 μL of Trifast/Trizol. 
After being harvested by pipeting up and down, the samples can be stored at -80o C. If so, in order to 
proceed, samples should be thawed and incubated for 5 minutes at room temperature.  
To obtain a fractionated solution of cellular content, 100 μL of chloroform were added, the samples were 
shaken vigorously for 15 seconds and incubated for 5 minutes at room temperature. Following a 
centrifugation of 15 minutes at 12000 g, the upper aqueous phase containing RNA was extracted. RNA 
was incubated on ice with 250 μL of isopropanol for 10 minutes. After centrifugation for 15 minutes at 
12000 g, the supernatant was removed and the pellet was washed two times with 500 μL of 75% ethanol 
interspersed by maximum speed centrifugation at 4oC for 5 minutes. After removing the ethanol, the 
pellet dried for 10 minutes, was resuspended with 20 μL of RNAse free water and dissolved at 55°C.  The 
RNA concentration was measured with the Nanodrop (DeNovix) equipment. 
 
cDNA synthesis 
cDNA synthesis was accomplished by mixing 1μg RNA with a master mix of 280 pmol oligo-dT primer, 
166 μM dNTPs, 1x M-MuL V Reverse transcriptase buffer, 100 U M-MuL V Reverse transcriptase, 20 U 
RNAse inhibitor and RNAse free water. This mixture was incubated for 10 minutes at room temperature 
and, afterwards, cDNA was via reverse transcription (Figure 12).  At this point cDNA can be stored at -
30°C. 
 
Figure 12 Reverse transcription PCR cycle of cDNA synthesis. cDNA was synthesized for 90 minutes at 42°C and 
the enzyme was inactivated for 20 minutes at 65°C 
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Polymerase chain reaction and DNA electrophoresis 
To check cDNA integrity, it should be analyzed by PCR (Figure 13) using primers designed to the intronic 
sequences of a standard, constitutively expressed housekeeping gene, and gel electrophoresis. 2 μl of 
each cDNA was used as template in the PCR reaction, together with 170 nM mouse GAPDH primers, 166 
μM dNTPs, 1x Reaction Buffer NZYTaq DNA Polymerase, 1,41 mM MgCl2, 2,5 U NZYTaq DNA Polymerase 
and Nuclease-free water.  
 
Figure 13 PCR cycle used to amplify GAPDH gene. The PCR started with an initial denaturation step for 3 minutes 
at 94°C, followed by 40 cycles of a denaturation-annealing-extension step, and a last final extension that last for 5 
minutes at 72°C. 
 
PCR products ran by DNA electrophoresis in a 1% agarose gel in 1x TAE. After the molten gel had 
partially cooled, Midori Green DNA Stain was added and the gel was poured into gel trays. Completely 
set and hardened gels were mounted into electrophoresis chambers and covered with TAE buffer. 
Samples for analysis were mixed with 1x Orange DNA Loading Dye (ThermoFisher) and loaded into the 
sample wells. Electrophoresis was carried out at 100 V for 40 minutes in 1x TAE running buffer, using 
O'GeneRuler DNA Ladder Mix (Thermo Fisher) to allow sizing and quantification. DNA in the gel was 
visualized and digital images were obtain using GelDoc (BioRad). 
 
Real-time Quantitative Polymerase Chain Reaction  
The primer sequences used for quantification of mouse IRF1 were fwd 5’ 
GGTCAGGACTTGGATATGGAA 3’ and rev 5’ AGTGGTGCTATCTGGTATAATGT and for mouse GAPDH 
were fwd 5’ GCC TTC CGT GTT CCT ACC 3’ and rev 5’ CCT GCT TCA CCA CCT TCT T 3’. All were 
previously described by Magalhães et al31. 
The real-time polymerase chain reaction mix was prepared with 2 μL of 1:10 diluted synthesized cDNA, 
10 μL of 2× iTaq SYBR Green Master Mix (BioRad) and each primer was added to a final concentration 
of 250 nM for a total volume of 20 μL. The fluorescence was measured after the extension step (Figure 
14), using the7500 Real-Time PCR System and its software (Applied Biosystems). After the 
thermocycling reaction, the melting step was performed with continuous measurement of fluorescence.  
Data analysis was performed using the 2−ΔΔCT method.  
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Figure 14 RT-qPCR cycling protocol. The reaction initiated by heating at 95°C for 3 min, followed by 40 cycles of 
a 12 seconds denaturation step at 95°C and a 30 seconds annealing/elongation step at 60°C. After the thermocycling 
reaction, the melting step was performed with continuous measurement of fluorescence 
 
4.2.6 Infection  
To perform infection with IAV, HSPB1-GFP HeLa and A549 cells were seeded witha density of 2x105 cells 
(day 0) for protein extraction protocol and 2.4x104 cells for immunofluorescence experiments, taking in 
consideration that both cell lines duplicate in 24 hours.  
The day after, cells were washed with Serum Free Media (SFM) [DMEM supplemented with Pen-Strep 
and Glutamine – without FBS because its inhibits virus entry] and infected with Influenza A virus PR8 
(4x107 pfu/ml) and the ΔNS1 mutant strain (that lacks the NS1 protein) (4.7x107 pfu/ml) at a MOI of 3, 
prepared in SFM. After, the plates are incubated for 5 minutes, mixing at room temperature, followed by 
a 35 minutes incubation at 37oC in 5% CO2. Complete media was then added (to stop the viruses to 
continue entering the cell) and the plates were again incubated for the desired times at 37oC in 5% CO2. 
 
4.2.7 Immunobloting 
Lysis and harvesting – total protein extraction and quantification 
After infection, cells were washed 1x with PBS and harvested with 500 μL of Empigen Lysis Buffer (ELB) 
suplemented with inhibitors per well (up&down). Samples were centrifuged for 20 minutes at 200 g at 
4°C. The supernatants were kept and total protein was quantified (can be stored at -20°C). During all 
procedures, cells remained on ice to avoid the activity of proteases. 
 
Insoluble protein fraction 
To isolate the insoluble protein fraction, the volume corresponding to 100µg of total protein was diluted 
in 80 µL of ELB and 20 µL of NP40 (10%). Samples were sonicated for 20 seconds (three times).  After 
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sonication cycles, samples undergone another centrifugation (16,000 g, 20 minutes at 4 °C). The 
supernatant was removed, the pellet was solubilized with 50µL of ELB.  
 
Protein Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Desired concentrations (μg) of protein extracts were diluted in 5x loading buffer (DTT and bromophenol 
blue) and denatured for 5 minutes at 95°C. After, samples were loaded alongside with a pre-stained 
protein marker (GRS Protein Marker Multicolour Tris-Glicine 4~20%, Grisp) in mini handcast gels 
prepared with 10-12% polyacrylamide resolving gel and 4% stacking gel. The electrophoretic chamber 
was filled with 1x concentrated Running Buffer and the electrophoresis was conducted for 2 hours, first 
at 80 V to allow the samples to pass through the stacking gel, and then at 110 V. Bromophenol blue 
presented in the loading buffer allowed sample running visualization.  
Gels obtained for total/insoluble protocol were stained with BlueSafe, according to the manufacturer’s 
instruction and the results were observed using the Odyssey scanner and its software (LI-COR, 
Biosciences, US). 
 
Western Blot and Immunodetection 
After protein’s separation, proteins were electro transferred onto a nitrocellulose membrane in the 
Trans-Blot® Turbo™ Transfer System for at 25 V, 0,4 A for 7 minutes.  
The membranes were washed three times, 5 minutes each, with 1x tris-saline buffer with tween 20 (TBS-
T) to take out the methanol residues and were blocked using 5% (w/w) low fat powder milk or 2% 
Bovine Serum Albumin (BSA) diluted in TBS-T for 1 hour at room temperature. Membrane staining was 
accomplished by incubation with primary antibodies at room temperature for 1 hour or at 4oC overnight, 
and the respective secondary antibodies during 1 hour at room temperature protected from light, under 
agitation. Between incubations, three washing steps of 5 minutes each with TBS-T were performed.   
Digital pictures of the stained membranes were obtained in the Odyssey scanner and analyzed in its 
software (LI-COR, Biosciences, US), using tubulin intensity as normalizer. The Odyssey system is 
equipped with two infrared channels for direct fluorescence detection on membranes at 700 and 800 
nm. 
 
4.2.8 Quantification methods 
Nucleic Acids quantification 
DNA and RNA quantification was performed using DeNovix. Since both nucleotides absorb at 260 nm, 
purification of the samples is required prior to measurement. The photometer measures simultaneously 
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the absorbance at 230, 260 and 280 and displays A260/A280 and A260/A230 ratios determining the 
contamination of the samples with protein specimens and organic compounds, respectively. The 
generally accepted 260/280 values are around 1.8 for pure DNA and 2.0 for RNA, while the 260/230 
values for nucleic acids usually range between 1.8 and 2.2. 
 
Bovine Serum Albumin Protein Assay 
Pierce™ Bovine Serum Albumin (BCA) Protein Assay Kit (Thermo Scientific) was performed to quantify 
total protein following the manufacturer´s instructions. The total extracts were incubated with the BCA 
reagent for 30 minutes at 37 °C, followed by absorbance measurement at 575 nm in a microplate reader.  
 
4.2.9 Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR associated 
system 9 (CRISPR/Cas9) for gene knockout 
Restriction digestion and Ligation 
Lentiviral CRISPR-Cas9 constructs were generated by cloning double-strand oligonucleotide inserts 
into a pSicoR-CRISPR-Cas9 lentiviral vector (RP418), puromycin resistance. 
RP418 vector was digested with BsmBI (Esp3I) Fast Digest restriction enzyme (together with 1x Fast 
Digest Buffer and 1 mM DTT) at 37oC for 30 minutes. Digested samples ran on 1% agarose gel in 1x 
concentrated TAE buffer at 120 V for 1 hour in 1x TAE running buffer. The bands of interest were excised 
under the UV light with a scalpel, followed by isolation and purification with NucleoSpin® Gel and PCR 
clean-up (Macherey-Nagel) as the protocol indicates. 
The Oligo-gRNA of interest were previously designed. After reconstruction, 10 µM of each primer were 
mixed together and annealed as the mixture was heated up to 95oC for 5 minutes and 10 minutes on ice. 
At this point, oligo-gRNA can be stored at 4oC for later usage. 
The ligation was performed using 10 ng of the linearized vector and 10 µl of gRNA and both were 
incubated with a T4 DNA ligase in NEBuffer U at 16°C overnight. The resulting plasmid was used to 
transform bacteria according to the electroporation protocol described before.  
 
Transfection and transduction (Retroviral infection of cells) 
Lentiviral RP418—OligoRNA constructs were transfected together with envelope and packaging 
plasmids, pCMV R8.81 and pMD2.G, into 293T cells for lentivirus production.  293T cells were seeded in 
a 10øcm plate with a density of 3x106 cells per plate. Transfection was performed using PEI, as 
previously described.  
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HFF cells were seeded in 6-well plates with a density of 0.75x105 cells, using 3 wells per condition. To 
perform transduction, the virus supernatant was filtered through a __ cm syringe. 5µ of polybrene was 
added to the medium and 3 mL were added to the cells. Centrifugal enhancement was performed at 2300 
rpm for 30 minutes. The medium was replaced 24 hours after the retroviral infection and cells were 
cultured for 48 hours. Plate the cells from each oligo-gRNA into 10 cm plate.  
 
Cells selection 
Growth medium was replaced with selective medium containing puromycin using a final concentration 
of 2µg/ml. Selection medium was replaced with normal growth medium after mock infected cells 
showed no survivors. Transduced cells were expanded and further characterized by Western Blot 
analysis. Additionally, single sell selection was performed according to Cell Cloning by Serial Dilution in 
96-well plates Protocol (Corning) and the clones were also characterized.   
 
4.2.10 Statistical Analysis 
Statistical analysis was achieved using Graph Pad Prism 7. Data were attained for the quantitative 
analysis of IRF1 mRNA from three independent experiments and represent the means ± standard error 
mean (SEM). To determine the statistical significance between the experimental groups the one-way 
ANOVA followed by Bonferroni’s multiple comparison tests were applied. P values of ≤0.05 were 
considered as significant. 
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CHAPTER V 
Results and Discussion 
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5.1 Human Cytomegalovirus and Innate Immunity 
 
Upon infection, intracellular RLR recognize viral components and activate a MAVS-mediated antiviral 
immune response, that culminates with the production of type I IFN and of pro-inflammatory cytokines. 
MAVS has been shown to localize at mitochondria32 and peroxisomes33, both comprising specific and 
complementary antiviral responses, although temporally and functionally different20,29. HCMV’s protein 
vMia is known to block apoptotic signaling pathways and subvert the mitochondria and peroxisome-
dependent host antiviral response31,41,54. 
Castanier et al54 reported that RLR activation promotes elongation of the mitochondrial networks, and 
further suggested that mitochondria elongation induces MAVS-mediated signaling, whereas its 
fragmentation has the opposite effect. Furthermore, the authors showed that vMIA promotes 
mitochondrial fragmentation and consequently impedes downstream MAVS signalling54.  Our group has 
previously demontrated that vMIA travels to peroxisomes via interaction with the Pex19 chaperone, 
where it interacts with MAVS and induces peroxisomes’ fragmentation30. However, this organelle 
morphology change is not essential for the role of vMIA on the evasion of the immune response30. Hence, 
both reports point towards two distinct mechanisms relating organelle’s fragmentation and its interplay 
with the inhibition of the antiviral response. 
In order to unravel these specific mechanisms, we proposed to analyze several vMIA mutants who lack 
different amino acid sequences, in order to map the domains responsible for either peroxisomal 
fragmentation or MAVS-dependent immune response. 
 
Mapping the vMIA domains responsible for organelles’ morphology change 
Goldmacher et al41 first characterized the amino-terminal 2–23 amino acid sequence of vMIA as 
necessary for both anti-apoptotic activity and mitochondrial targeting. A mutant lacking the 2-23 
sequence abrogated vMIA anti-apoptotic function and evidently altered its staining pattern to 
cytoplasm, as it is neither evidently  translocated to the ER nor into mito45.  
Further studies44,46,116 identified two necessary and sufficient domains required for its antiapoptotic 
activity, namely 5-34 and 118-147. Hayajneh et al44 showed that a mini vMIA Δ35-112/Δ148-163, 
consisting essentially of just the two functional domains, retained antiapoptotic function; and moreover 
demonstrated that the mitochondrial localization signal is located within the 2-30 segment of vMIA. 
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It is also known that vMIA inhibits apoptosis by binding and sequestering Bax at mitochondria46,116, 
demonstrating that there is a strong correlation between the anti-apoptotic function of vMIA and its 
ability to bind and relocate Bax. 
The characteristics of some of the vMIA mutants used in the studies mentioned above are represented 
and summarized in Figure 15.   
 
Figure 15 Structural and functional characterization of vMIA and different sequence-deletion vMIA mutants. 
Several studies have defined two essential and sufficient anti-apoptotic domains (in black) in vMIA, with either a 
mitochondrial localization signal or bax-binding activity.  
 
To determine whether these mutants co-localize with peroxisomes and analyse their possible effect on 
the organelle’s morphology, their myc-tagged constructs were transfected into Mef cells that express 
MAVS solely at peroxisomes (MAVS PEX cells)33. After 24h, these cells were subjected to 
immunolocalization analyses with antibodies against Myc and PMP70 to stain the vMIA mutants and 
peroxisomes, respectively. 
The obtained results (Figure 16 B) show that all the tested mutants co-localize with peroxisomes. In 
order to analyse the effect of these mutants on peroxisome morphology we compared the size and shape 
of the organelles with the ones presented in the control untransfected MAVS-PEX cells (Figure 16 A a). 
where most peroxisomes assume an elongated or rod-shape. Hence, in this study we considered the cells 
containing “fragmented peroxisomes” as those whose peroxisomes were significantly smaller and in 
higher number when compared to the control cells.  
Upon overexpression of the Δ23-34 mutant, one can observe an apparent mitochondria and peroxisome 
fragmentation. This peroxisomal morphology change is not observed upon overexpression of the Δ115-
130 mutant, (consistently to what is observed for mitochondria). On the other hand, the Δ131-147 
mutant seems to somehow affect peroxisome morphology as peroxisomes appear rounder, larger and 
in higher number when compared to control cells. To note also that a higher degree of co-localization 
with this organelle is observed for this mutant in comparison with the other two and wild-type vMia. 
Whether this morphology change reflects a peroxisomal proliferation remains to be investigate.  
Previous studies have shown that only the Δ115-130 and Δ131-147 mutants co-localize with 
mitochondria44,45. Although we have not yet performed analyses with mitochondrial markers, in our 
study all the three mutants seem to assume a typical mitochondrial localization pattern. Δ115-130 
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seems to have no effect on mitochondria morphology and both Δ23-34 and Δ131-147 seem to induce 
organelle’s fragmentation. The results obtained for the Δ23-34 mutant seem to contradict the 
localization pattern that has been previously shown41. Naturally, these results have to be confirmed with 
quantification studies using mitochondrial markers. Nevertheless, and similarly to peroxisomes, the 
Δ115-130 domain seems to be necessary for the organelle’s fragmentation. 
 
Figure 16 Peroxisomal morphology and vMIA mutants localization in MAVS PEX cells. Confocal images from 
immunofluorescence staining of peroxisomes and vMIA mutants with PMP70 and myc, respectively. (A a) 
untransfected MAVS-PEX cells 31 (B) cells transfected with vMIA (a-c) Δ23-34, (d-f) Δ115-130 and (g-i) Δ131-147. 
Bars correspond to 10μm. Arrows indicate co-localization loci between Myc-vMIA mutants and peroxisomes. 
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These results seem to indicate than none of the deleted domains has affected the localization of the pro-
tein at peroxisomes. Importantly, the 115-130 domain seems to be necessary for the organelle’s frag-
mentation to take place. However, in this study only a few cells (10-20 in each case) were analysed. A 
quantitative analysis of a higher number of cells (currently being performed) is obviously needed to 
obtain a solid conclusion. 
 
Mapping the vMIA domains responsible for the inhibition of innate immune response 
The peroxisomal MAVS-dependent antiviral pathway is responsible for the early induction of ISGs such 
as IRF133. To study the effect of the previously mentioned vMIA mutants on the inhibition of the 
peroxisomal antiviral response, they were overexpressed in MAVS-PEX cells and IRF1 mRNA production 
was quantified by RT-qPCR.  Twenty-four hours after the transfection of the mutants, the cellular 
antiviral response was stimulated by overexpressing a constitutively active version of RIG-I, RIG-I-
CARD31,117, composed solely by the CARD domains of RIG-I and allowing their direct exposition to MAVS 
without needing an activator ligand for RIG-I, hence mimicking a viral infection.  
As shown in Figure 17, the presence of all three vMia mutants resulted in the inhibition of the IRF1 
mRNA production induced by the presence of RIG-I-CARD.  
 
Figure 17 Deletion mutants of vMIA inhibit the peroxisome-dependent innate immunity signaling. Mefs 
MAVS PEX cells were transfected with deletion mutants of vMIA and stimulated with GFP-RIG-I-CARD. IRF1 mRNA 
expression was analyzed by RT-qPCR. GAPDH was used as a normalizer gene. For the 131-147, data represents 
the means ± SEM of three independent experiments. Statistical analysis was performed using one-way ANOVA 
followed by Bonferroni’s multiple comparison. Error bars represent SEM. *p≤0.05, **p≤0.01, compared with control. 
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These results demonstrate than none of the domains that are absent in these mutants is the one 
responsible for the inhibition of the peroxisome-dependent antiviral response. Our results, together 
with what is already known in the literature, are summarized in Figure 18. 
As it has been previously shown than vMIA interacts with MAVS at peroxisomes, it is highly likely that 
these mutants remain able to interact with this protein at the peroxisomal membrane. However, further 
experiments will be performed in order to confirm this interaction as well as to identify the specific 
domain of the protein that is responsible for the inhibition of the cellular immune response. We are 
currently analyzing a mutant with a deletion on the 2-23 region41. Whether similar results would be 
obtained for the mitochondria-dependent pathway remains to be investigated and will be done in the 
near future. 
 
 
Anti-apoptotic 
activity 
Bax-binding 
activity 
Cellular 
localization 
Organelles’ 
fragmentation 
Inhibition of the peroxisome-
dependent antiviral response  
vMIA + + Mito, ER, Golgi, PO Mito, PO + 
Δ23-34 - + Cyto, ER, Mito, PO Mito, PO + 
Δ115-130 - - Mito, ER, PO none + 
Δ131-147 - - Mito, ER, PO Mito, PO + 
Figure 18 Complementary characterization of vMIA and its different mutants. Obtained results with this 
project are underlined.  
 
Creation of a PEX19 KO cell line 
To further study the importance of the peroxisomal MAVS pathway on the antiviral immune response 
upon HCMV infection, we decided to create a stable cell line in which the vMIA-dependent inhibition of 
this pathway is compromised. It has been shown that vMIA travels to peroxisomes via interaction with  
Pex1931,a 33kDa protein that acts both as a cytosolic chaperone and as an import receptor for 
peroxisomal membrane proteins (PMPs)36. It was hypothesized that, in the absence of Pex19, vMIA 
would not be able to reach the peroxisomal membrane, interact with MAVS and consequently inhibit the 
immune response. 
Therefore, we decided to create a Pex19 KO cell line of human foreskin fibroblasts (HFF), a cell line that 
is commonly infected by HCMV, using the CRISPR/Cas9 system (Figure 19). 
Lentiviral CRISPR/Cas9 constructs were generated by cloning three double-strand Pex19 
oligonucleotide inserts into a puromycin resistance pSicoR-CRISPR-Cas9 (RP418) lentiviral vector. 
Lentiviral constructs were transfected with packaging plasmids, pCMV R8.81 and pMD2.G, into 293T 
cells for lentivirus production. Transduced HFF cells were expanded and further characterized by 
Western Blot analysis. 
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Figure 19 Schematic and shorten representation of CRISPR/Cas9 system. (1) Lentivirus production in 293T 
cells results from co-transfection of an envelope vestor (pMD2.G), a packaging vector (pCMV R8.81) and a pSicoR-
CRISPR-Cas9 lentiviral vector (RP418) containing a PEX19 oligonucleotide insert. (2) Transduction to HFF cells and 
supplementary treatment with puromycin allowed KO cells selection. 
 
The results, presented in Figure 20, suggested that the KO was effective for all oligonucleotides.  
 
Figure 20 CRISPR/Cas9 PEX19 KO cell lines. Western blot analysis showing an effective KO of Pex19 in HFF cells. 
Actin was used as the loading control. 
 
Further single cell selection is currently being performed. Once the final KO cells are obtained, these will 
be infected with HCMV and analyses of the intracellular vMia localization, organelle morphology, and 
virus production will be performed. 
 
Study of the vMIA analogue in MCMV 
HCMV replicates very slowly in cell culture and only a few cell lines (mostly HFF) are permissive to 
infection by this virus. Furthermore, in vivo infection studies with HCMV are evidently impossible. In 
order to overcome these drawbacks we decided to test whether we could complement our studies with 
the MCMV, a natural mouse pathogen  that shares a high degree of sequence homology and biology with 
HCMV3. Besides being able to perform animal studies, the use of this virus would allow us to study 
infection in our Mefs MAVS-Pex cells as well as Mefs MAVS KO and Mefs MAVS-MITO (MAVS solely at 
mitochondria) cells, which are also available in the lab. Concretely, we proposed to study the m38.5 
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protein, which is referred as the MCMV analog to vMIA59,60. Although m38.5 and vMIA share little 
sequence similarity, their genes are located at analogous positions within the viral genomes and both 
share similar functions, as both localize at mitochondria where they bind Bax in order to prevent its 
activation and mediated apoptosis57–59.  
We decided to analyse the intracellular localization of m38.5 as well as its effect of organelle morphology 
and inhibition of the cellular antiviral response, in order to establish the similarity between this protein 
and HCMV vMia.  Thus, we performed similar experiments as the previously described for the vMIA 
mutants. To verify the localization of m38.5, MAVS PEX cells were transfected with a HA-m38.5 construct 
and were subjected to immunofluorescence analysis with antibodies against the peroxisomal marker 
PMP70 and HA.  
Analysis by confocal microscopy (Figure 21) showed an expected typical mitochondrial localization 
pattern as well as a co-localization with the peroxisomal marker. A preliminary analysis of the 
peroxisome morphology seems to indicate that, similarly to vMia, m38.5 induces the organelle’s 
fragmentation. However, further quantification analysis will be performed in order to confirm this fact. 
 
 
Figure 21 Peroxisomal morphology and m38.5 localization within transfected MAVS PEX cells. Confocal 
images of (a) PMP70, (b) Myc and (c) merge image of a and b. Bar represents 10μm. Arrows indicate co-localization 
loci between Myc-vMIA mutants and the peroxisomal marker. 
 
Moreover, to examine the effect of m38.5 on the peroxisome-dependent MAVS pathway, IRF1 mRNA 
production was quantified by RT-qPCR. MAVS PEX cells were transfected with m38.5 for 24 hours and 
stimulated with GFP-RIG-I-CARD for 6 hours. The RT-qPCR results (Figure 22) indicate that, similarly to 
vMia, m38.5 inhibits the peroxisomal-MAVS antiviral signaling. 
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Figure 22 m38.5 inhibits MAVS PEX innate immunity signaling. Mefs MAVS PEX cells with MAVS only at 
peroxisomes were transfected with m38.5 and stimulated with GFP-RIG-I-CARD. Analysis of IRF1 mRNA expression 
by RT-qPCR showed that it is impaired by m38.5. GAPDH was used as a normalizer gene. Data represents the means 
± SEM of three independent experiments. Statistical analysis was performed using one-way ANOVA followed by 
Bonferroni’s multiple comparison. Error bars represent SEM. *p≤0.05, **p≤0.01, compared with control. 
 
In conclusion, similarly to HCMV vMia, the MCMV m38.5 seems to localize at peroxisomes, induce the 
organelle’s fragmentation and clearly inhibit the peroxisome-dependent antiviral immune response. 
Although further studies must be performed, namely on the analysis of mitochondria and mitochondria-
dependent antiviral response, our results indicate that this virus may be used to complement our study 
with HCMV.  
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5.2 Influenza A Virus and Quality Control Machinery 
 
Previous studies have shown that during viral infection specialized sites for viral replication are formed, 
resulting in the creation of insoluble aggregates or inclusions, which can be either part of innate cellular 
response90 or used by viruses as scaffolds for replication, assembly and host immune system evasion91. 
As previously mentioned, IAV uses the aggresome processing machinery for host cell entry, specifically 
during uncoating94,95.   
In order to determine whether IAV infection leads to aggresomal formation, we infected HeLa cells that 
constitutively express a GFP-tagged HSPB1 (also named HSP27), a cellular marker form is folded 
proteins, and possibly aggregation (HeLa HSPB1-GFP cells). This protein is normally localized at the 
cytosol and relocates in foci upon stress conditions. Furthermore, the ProteoStat® Aggresome Detection 
Kit was used to complement our studies, as   it is used to specifically detect denatured and/or misfolded 
protein aggregates and inclusion bodies. It contains a novel 488 nm excitable red fluorescent molecular 
dye to specifically detect denatured protein cargo within aggresomes and aggresome-like inclusion 
bodies in fixed and permeabilized cells.  
HeLa HSPB1-GFP cells were infected with PR8 and ΔNS1 viruses and fixed cells for immunofluorescence 
analysis were collected 1 hour post infection (hpi), 2hpi, 4hpi, 8hpi, 12hpi and 16hpi. PR8 stands for the 
wild-type of influenza strain A/Puerto Rico/8/1934 (H1N1), while ΔNS1 stands for a NS1-deleted 
mutant from the same strain. The NS1 protein is a non-essential virulence factor that has been described 
as essential for inhibition of host immune responses, especially through the limitation of IFN 
production118,119. Thus, the ΔNS1 virus mutant is less capable of subvert antiviral cellular response and 
we expected a slower life cycle, comparing to PR8 virus. 
After overcoming some technical constrains on the establishment of the IAV infection procedure in our 
laboratory, we were able to perform a preliminary analysis by confocal microscopy which indicated the 
formation of aggregates/aggresomes in ΔNS1 infected cells (Figure 23) at a time-point where the vRNP 
are not yet present in the nucleus. These aggregates tend to disappear in later time points (data not 
shown). This preliminary analysis did not show the presence of protein aggregates in PR8-infected cells.  
It was previously shown by that Banerjee et al95 that IAV takes advantage of the aggresome processing 
machinery for host cell entry, using immunoprecipitation and immune colocalization assays between 
viral and aggresome machinery-associated proteins. They demonstrated that IAV requires the ubiquitin-
binding function of HDAC6 for capsid uncoating and viral content release into the cytosol, including M1 
protein and the vRNPs that are further transported to the nucleus (Figure 10). Besides HDAC6, other key 
components of the aggresome processing machinery, namely dynein, dynactin, and myosin II, proved to 
be also required for an efficient infection95.  
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 Therefore, our results are somewhat consistent with these, since we observe aggresome formation 
before nuclear vRNP staining. Taking Banerjee et al95 results in consideration, we hypothesize that these 
aggregates may correspond to sites of uncoating and vRNP release. In future studies, we propose to 
characterize the originated aggresomes in terms of protein content.  
 
Figure 23 Aggresomal formation in HeLa HSPB1-GFP cells infected with ΔNS1 IAV. Confocal images of (a) 
cellular HSPB1-GFP, (b) Proteostat dye, (c) viral NP, (d) nuclear DAPI, and (e) merge image. Bar represents 10μm. 
Arrows indicate protein aggregates. 
 
Simultaneously, we have analyzed the insoluble protein fraction within the cells throughout the infec-
tion-course. To conduct the experiment, HeLa HSPB1-GFP cells were infected with PR8 and ΔNS1, total 
protein was extracted using ELB supplemented with protease inhibitors, from which a detergent-insol-
uble fraction was obtained. Protein samples ran by SDS-PAGE, were stained with BlueSafe, and quanti-
fied (Figure 24). Our preliminary results indicate an increase in the insoluble protein fraction upon IAV 
infection, mainly with the ΔNS1 virus. These results suggest that there may occur an accumulation of 
misfolded aggregation-prone proteins upon IAV infection. However, more replicated need to be per-
formed in or to take a more solid conclusion.   
It is known that viral infection can lead to accumulation of unfolded proteins and its aggregation within 
the ER, inducing ER stress and consequently the UPR97. Thus, we proposed to analyze UPR induction 
through ATF6 activation. In cells undergoing ER stress, ATF6 (75 kDa) is cleaved into an active cytosolic 
fragment (ATF6f, 50 kDa) that activates the molecular chaperone transcription to increase ER folding 
capacity. 
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A 
 
B  Insoluble/Total Ratio 
 8hpi 12hpi 16hpi 
mock 1.000 1.000 1.000 
PR8 1.529 1.071 0.957 
ΔNS1 1.542 1.171 1.364 
Figure 24 Caracterization of insoluble protein fraction upon infection at different time points, normalized 
to the total fraction. (A) SDS PAGE of total and insoluble protein fraction of infection with both different viruses, 
at 8, 12 and 16hpi. (B) Dermination of the insoluble/total ration of each condition in relation to mock cells. 
 
To our knowledge, the previous results on this study are somehow contradictory. Hassan et al.113 
reported that IAV modulates the stress response in the setting of a pre-existing stress, by decreasing the 
activation of the ATF6 pathway; Roberson et al.114 showed, in murine cells, that IAV infection induces 
ER-stress via ATF6 activation; and Landeras-Bueno et al.115 found that IAV does not downregulate ATF6.  
In our study, the cleavage of ATF6 into ATF6f in human cells was analyzed by immunoblotting. HeLa 
HSPB1-GFP cells were infected and proteins were extracted as previously described. The obtained 
results suggest an increment of ATF6 cleavage with time upon PR8 and ΔNS1virus infection (Figure 25). 
 
These results, although preliminary, corroborate those from Roberson et al114 that presented in MTEC 
cells an increase in ATF6 by Western blotting at 24hpi, which was sustained up to 48hpi, using a mouse-
adapted IAV PR/8/34 (H1N1).  
However, our results are inconsistent with Hassan et al113 that showed no activation of ATF6 upon 
infection, but an inhibition of a preexisting induced ER stress. In this case, the authors also studied IAV 
PR/8/34 (H1N1) influence on ATF6 pathway at similar times of infection, explicitly 12hpi, however with 
a different approach. They rely on HTBE cells infected with a multiplicity of infection (MOI) of 1, and 
measured the ATF6 inhibition using q-RT-PCR of some ATF6-driven stress genes. In this study, we 
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followed a different approach by trying to characterize, in a different cell line, the ATF6 pathway 
activation by directly detecting and measuring its cleavage. This is not impeditive that these genes are 
inhibited downstream ATF6 cleavage, for instance as a consequence of crosstalk with other responses 
happening concomitantly within the cell. 
 
B ATF6f/tubulin ratio 
 8hpi 12hpi 16hpi 
mock 1 1 1 
PR8 2.59 1.12 1.68 
ΔNS1 3.19 2.11 3.23 
 
Figure 25 ATF6 is activated upon IAV infection. (A) Protein extracted from HeLa HSPB1-GFP cells infected with 
both PR8 and ΔNS1 viruses for 8, 12 and 16 hpi, were analyzed by immunoblotting for ATF6 fragmentation. Tubulin 
was used as loading control. (B) Determination of ATF6f/tubulin ratio in relation to mock cells. 
 
In parallel, we are currently optimizing the antibodies for PERK, IRE1 and their phosphorylated forms, 
in order to further analyze the PERK and IRE1 pathways. 
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CONCLUDING REMARKS 
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Human Cytomegalovirus and Innate Immunity 
 
HCMV vMIA has been shown to localize at mitochondria and peroxisomes, induce their fragmentation 
and, more importantly, inhibit the cellular antiviral response that is established at these organelles. With 
the objective of unraveling the mechanisms by which vMia is able to exert these changes, we decided to 
study several mutants of these proteins that lack specific aminoacid sequences. In this way, we were 
able to conclude that the 115-130 amino acid sequence is likely the domain responsible for peroxisomes 
and mitochondria fragmentation. However, none of the studied mutants was incapable of inhibiting the 
peroxisome-dependent immune response. We are currently testing other mutants and performing 
further analysis in order to confirm and expand our results. We have also initiated the creation of a HFF 
Pex19 KO cell line using CRISPR/Cas9. As vMia is not able to reach the peroxisomes without the help of 
Pex19, once this cell line is fully prepared, we will be able to infect it with HCMV and analyse whether 
(and where in the virus life-cycle) the peroxisome-dependent antiviral pathway is important for 
inhibiting viral proliferation. Moreover, we have demonstrated that the MCMV m38.5 seems to act 
similarly to vMIA, in what organelle’s morphology changes and inhibition of the peroxisomal antiviral 
response are concerned. We are now, hence, able to use this virus to complement our results on HCMV 
and able to, in the future, replicate our experiments in infected animal models.  
 
Influenza A Virus and Quality Control Machinery 
 
During infection, the formation of specialized sites of viral replication can result in the formation of insoluble 
aggregates or inclusions that may be part of innate cellular response that recognizes and sequesters viral 
components, or possibly will be used by viruses as scaffolds for anchoring either viral and host proteins 
required for replication and assembly, as a protection from host defense. It is known that IAV requires HDAC6 
ubiquitin-binding function, taking advantage of the aggresome processing machinery for host cell entry and 
especially for capsid uncoating. Also, during productive viral infection, as in the case of IAV, large amounts 
of viral proteins are synthesized and modified in infected cells, leading to rapid accumulation of viral proteins 
and disruption of the ER homeostasis and induction of UPR.  Our results, although preliminary, indicate that 
there is formation of aggresomes upon infection, as well as an accumulation of insoluble proteins in IAV-
infected cells. Naturally, these results must be complemented with further replicates and, if confirmed, we will 
characterize aggresome dynamics and composition over the course of infection. Our results also indicate that 
the UPR ATF6 pathway is influenced by IAV infection. These results have to be confirmed with more 
replicates and the behavior of the other two UPR pathways upon IAV infection will also be studied in the near 
future. 
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“Cytomegalovirus evasion from the RIG-I/MAVS-dependent antiviral response follows discting 
mechanisms in peroxisomes and mitochondria.”, manuscript in preparation. 
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